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The radiation Sensitization potential of a candidate com 
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conditions. Compounds determined to have radiation Sensi 
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atheroma, tumors and other neoplastic tissue as well as other 
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METHOD AND COMPOSITIONS FOR 
TREATING ATHEROMA, TUMORS AND 
OTHER NEOPLASTIC TISSUE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This is a continuation-in-part of U.S. patent application 
Ser. No. 09/430,505 filed Oct. 29, 1999, now abandoned 
converted to provisional U.S. Patent Application Ser. No. 
60/287,588, filed Oct. 29, 1999, incorporated herein by 
reference. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to novel methods and pharmaceu 
tical formulations for treating atheroma, tumors and other 
neoplastic tissue, as well as other conditions that are respon 
Sive to the induction of targeted oxidative StreSS. This 
invention also relates to novel methods for determining the 
radiation Sensitization potential of a compound. 
2. Publications Cited by Reference 
Certain publications are cited in this application through 
the use of the following SuperScript numbers: 
Buettner, et al., Radiation Research, Catalytic Metals, 
AScorbate and Free Radicals. Combinations to Avoid, 
145:532–541 (1996) 
* Isoda, et al., J. Cancer Research, Change in Ascorbate 
Radical Production in an Irradiated Experimental Tumor 
with Increased Tumor Size, 56:5741-5744 (1996) 
Riley, Int. J. Radiat. Biol., Free Radical in biology: 
oxidative Stress and the effects of ionizing radiation, 
65(1):27–33 (1994) 
* Sessler, et al., J. Phys. Chem. A, One-Electron Reduction 
and Oxidation Studies of the Radiations Sensitizer Gado 
linium (III) Texaphyrin (PCI-120) and Other Water 
Soluble Metallotexaphyrins, 103: 787-794 (1999) 
Adams, et al., Radiation Res., 67:9-20 (1976) 
Riley, Int. J. Radiat. Biol., Free Radicals in Biology: 
Oxidative Stress and the Effects of Ionizing Radiation, 
65(1):27–33 (1994) 
7 Magda, et al., U.S. Pat. No. 5,798,491, Multi-Mechanistic 
Chemical Cleavage Using Certain Metal Complexes, 
issued Aug. 25, 1999 
Young, et al., U.S. Pat. No. 5,776,925, Methods for Cancer 
ChemOSensitization, issued Jul. 7, 1998 
Sessler, et al., U.S. Pat. No. 5,622,946, Radiation Sensi 
tization Using Texaphyrins, issued Apr. 22, 1997 
9 Sessler, et al., U.S. Pat. No. 5,457,183, Hydroxylated 
Texaphyrins, issued Oct. 10, 1995 
' Sessler, et al., Accounts of Chem. Res., Texaphyrins: 
Synthesis and Applications, 27:43-50 (1994) 
'' Hemmi, et al., U.S. Pat. No. 5,599.928, Texaphyrin 
Compounds Having Improved Functionalization, issued 
Feb. 4, 1997 
'Young, et al., Investigative Radiology, 29:330–338 (1994) 
'' Mosmann, J. Immunol. Methods, 65:55-63 (1983) 
Lin, et al., Analytical Biochemistry, The Cytotoxic Activ 
ity of Hematoheme. Evidence for Two Different 
Mechanisms, 161:323-331 (1987) 
Volpin, et al., WO097/03666, EP 0786 253 A1, U.S. Pat. 
No. 6,004,953, Agent for Suppressing Tumor Growth 
All of the above publications are herein incorporated by 
reference in their entirety to the Same extent as if each 
individual publication was specifically and individually 











3. Background Information 
The treatment of Solid mammalian tumors with Ionizing 
radiation involves the in Situ generation of hydroxyl radicals 
and other reactive oxygen Species which, due to the focus 
ability of the ionizing radiation are primarily located in the 
tumor, i.e., in tumor cells. These reactive species possess 
extreme oxidizing properties which oxidize biomolecules in 
vivo thereby interfering with cellular metabolism." For 
example, it is reported that ionizing radiation, Such as X-rays 
and Y-rays, induces irreversible damage to cellular DNA 
through production of hydroxyl radicals and other reactive 
oxygen species in the cell leading to cell death or initia 
tion of the mechanism of apoptosis." 
One generally accepted mechanism of the cellular effect 
of ionizing radiation is initial damage inflicted to the cells 
DNA by reactive oxygen species generated by the ionizing 
radiation. In the presence of molecular oxygen, this damage 
is largely irreparable. Contrarily, in the absence of molecular 
oxygen (Such as hypoxic cells), cellular antioxidants Such as 
ascorbate and NAD(P)H can act to repair damage to the 
tumor DNA. 
Tumor treatment via the use of ionizing radiation can be 
enhanced by increasing the radioSensitivity of the tumor 
cells. One method Suggested for enhancing radioSensitivity 
has been the external administration of a compound having 
a high affinity for electrons, which ideally localizes in the 
tumor. Proposed radiation Sensitizers include compounds 
Such as halogenated pyrimidines, nitroimidazoles and gado 
linium (III) complexes of the pentadentate macrocycle texa 
phyrin." Motexafon gadolinium (a gadolinium (III) texaphy 
rin complex) is currently in Phase III clinical trials for the 
treatment of brain metastases." 
Phthalocyanine and naphthalocyanine poly dentate 
ligands of the transition metals cobalt and iron have been 
described as Suppressing the growth of tumor cells when 
administered in combination with a biogenic reductant Such 
as ascorbic acid.' 
The observation that radiation Sensitization occurs as a 
function of redox potential gave rise to the proposal that 
Such compounds function by interception of aqueous 
electrons, thus preventing their recombination with cyto 
toxic radicals. Subsequent evidence showing a lack of 
radiation Sensitization activity for lutetium (III) texaphyrin 
in animal models notwithstanding the rapidity of reaction 
between this complex and hydroxyl radicals under pulsed 
radiolytic conditions and minimal apparent nuclear local 
ization Suggest that this proposal might not fully explain the 
mechanism by which the gadolinium teXaphyrins act as 
radiosenstizers." 
In View of the above, an understanding of the mechanism 
for radioSentization of tumor cells would be particularly 
helpful. Such an understanding could be used for testing in 
the discovery of new compounds useful as radiation Sensi 
tizers as well as in maximizing the therapeutic effect 
achieved by use of Such compounds in the presence or the 
absense of ionizing radiation. 
SUMMARY OF THE INVENTION 
This invention is premised upon the unexpected observa 
tion that the known motexafin gadolium radiation Sensitizer 
acts to catalyze the oxidation of NAD(P)H, ascorbate and 
other reducing agents under approximate physiological 
conditions, leading to reactive oxygen species generation. 
Depletion of these reducing agents will inhibit biochemical 
pathways that in Vivo utilize reducing agents to effect repair 
of the damage inflicted by reactive oxygen Species. 
Additionally, Since hydrogen peroxide is recognized as 
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probably the most Significant of the reactive oxygen 
species, the generation of hydrogen peroxide will facilitate 
oxidative attack on the tumor or other tissue where it is 
produced. 
Moreover, this discovery that motexafin gadolium acts to 
catalyze the oxidation of reducing agents under approximate 
physiological conditions to produce one or more reactive 
oxygen species Such as Superoxide and hydrogen peroxide, 
Serves as a basis to assess the radiation Sensitizing potential 
of other compounds. Specifically, a candidate compound can 
be Screened to determine its ability to generate one or more 
reactive oxygen Species under appropriate conditions. In 
turn, the amount of reactive oxygen Species So produced is 
then correlated to the radiation Sensitizing ability of the 
compound. Accordingly, in one of its method aspects, this 
invention is directed to a method for determining the radia 
tion Sensitization potential of a compound by the Steps of: 
a) introducing a compound to be tested into an aqueous 
Solution of a cellular metabolite having a Standard biochemi 
cal reduction potential more negative than the Standard 
biochemical reduction of oxygen/hydrogen peroxide; 
b) monitoring the Solution for the occurrence of a reaction 
that produces one or more reactive oxygen Species, and 
c) determining whether the compound has potential radia 
tion Sensitization activity, wherein the potential for radiation 
Sensitization activity correlates to the occurrence of a reac 
tion that produces one or more reactive oxygen Species. 
The reaction that produces a reactive oxygen Species can 
be monitored in numerous manners as is well known to the 
skilled artisan, by measuring one or more of depletion of 
oxygen, production of hydrogen peroxide, decreased con 
centration of the cellular metabolite, or generation of an 
oxidation product of the cellular metabolite. The cellular 
metabolite is preferably a compound Selected from the group 
consisting of ascorbate, NADPH, NADH, FADH and 
reduced glutathione. Even more preferably, the cellular 
metabolite is ascorbate or NADPH. 
In another embodiment, a compound which is determined 
to have radiation Sensitization potential by a method of the 
present invention can be administered to a mammalian host 
bearing a tumor and the tumor is Subsequently exposed to 
ionizing radiation. 
In still another embodiment there is provided a method for 
killing a tumor cells by: 
a) administering to the tumor cell a compound (other than 
a texaphyrin) that catalyzes the production of one or more 
reactive oxygen Species from a cellular metabolite having a 
Standard biochemical reduction potential more negative than 
the Standard biochemical reduction of oxygen/hydrogen 
peroxide; and 
b) exposing the cell to ionizing radiation. Preferably, the 
compound preferentially accumulates in tumor cells, e.g., as 
do porphyrin derivatives. One preferred compound is Fe(III) 
porphyrin. 
The knowledge that certain compounds exhibiting radia 
tion Sensitizing properties can catalytically effect the pro 
duction of one or more reactive oxygen Species from cellular 
metabolites having a biochemical reduction potential more 
negative than oxygen/hydrogen peroxide also Serves as a 
basis for a method to enhance the rate of tumor cell death by 
co-administration of a thiol-depleting compound to the cell. 
Such a thiol-depleting compound will reduce the level of 
thiol reducing agents Such as glutathione thereby removing 
essential components of the metabolic pathways for repair 












Accordingly, in another of its method aspects, this inven 
tion is directed to a method for killing a tumor cell, which 
method comprises: 
a) Selecting a compound having radiation sensitization 
potential as per above; 
b) administering said compound to the tumor cell; and 
c) co-administering to the tumor cell a thiol-depleting 
agent. Preferably, the radiation Sensitizing compound 
Selected in Step a) above is a texaphyrin and the thiol 
depleting agent is buthionine Sulfoximine. 
The above method has applicability in the treatment of 
cancer in a patient. When So applied, this invention provides 
for a method of treatment of cancer comprising administer 
ing to a patient Suffering therewith an effective amount of a 
teXaphyrin radiation Sensitzer, an effective amount of a 
thiol-depleting agent, and an effective amount of ionizing 
radiation. 
In yet another of its method aspects, this invention is 
directed to a method for killing a tumor cell, which method 
comprises: 
a) administering to said cell a compound that catalyzes the 
production of one or more reactive oxygen species from a 
cellular metabolite having a Standard biochemical reduction 
potential more negative than the Standard biochemical 
reduction of oxygen/hydrogen peroxide; and 
b) co-administering to said cell a second agent Selected 
from the group consisting of DNA alkylators, topoisomerase 
inhibitors, redox cycling agents, thiol-depleting agents, 
metabolic inhibitors, and mitochondrial inhibitors. Preferred 
DNA alkylators include carmustine. Preferred redox cycling 
agents include alloxan, phenazine methoSulfate, menadione, 
copper/putrescine/pyridine, methylene blue, paraduat, 
doxorubicin, bleomycin, and ruthenium (II) tris-(1,10 
phenanthroline-5,6-dione). Preferrred thiol-depleting agents 
include buthionine Sulfoximine and diethyl maleate. Pre 
ferred metabolic inhibitors include folic acid analogs (e.g., 
methotrexate and trimetrexate), pyrimidine analogs (e.g., 
fluorouracil, floxuridine, cytarabine and azacitidine), and 
purine analogs and related inhibitors (e.g., mercaptopurine, 
thioguanine, pentostatin and fludarabine). Preferred mito 
chondrial inhibitors include oligomycin and antimycin A. In 
another preferred embodiment, this method for killing tumor 
cells includes the additional Step of exposing the cell to 
ionizing radiation. 
In another, but related aspect of the invention, a first agent 
Selected from the group consisting of DNA alkylators, 
topoisomerase inhibitors, redox cycling agents, thiol 
depleting agents, metabolic inhibitors, and mitochondrial 
inhibitorS is co-administered with a Second agent that cata 
lyzes the production of one or more reactive oxygen Species 
from a cellular metabolite having a Standard biochemical 
reduction potential more negative than the Standard bio 
chemical reduction of oxygen/hydrogen peroxide, to a Sub 
ject having a condition (other than a tumor or atheroma) 
typically treated with Such first agent. 
Still further, in another aspect of this invention, there is 
provided a method of Selectively killing cells in a mamma 
lian host bearing a tumor or atheroma, which method 
comprises: 
a) administering to said mammalian host an agent that 
catalyzes the production of one or more reactive oxygen 
Species from an intracellular reducing agent, preferably 
ascorbate or NAD(P)H; 
b) optionally, allowing Sufficient time for said agent to 
preferentially accumulate in the cells of the tumor or 
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atheroma; and c) administering to said mammalian host a 
Source or precursor of the reducing agent Such as to increase 
the reactive oxygen Species production in the tumor or 
atheroma. 
In one preferred embodiment, this method further 
includes the Steps of exposing the tumor or atheroma to 
ionizing radiation. In another preferred embodiment, the 
agent employed in this method is motexafin gadolium or 
motexafin lutetium or combinations thereof. 
In yet another aspect of this invention, there is provided a 
method of treating a mammalian host bearing a tumor or an 
atheroma comprising administering to that host a therapeu 
tically effective amount of a combination of motexafin 
gadolinium and motexafin lutetium and exposing the tumor 
or atheroma to ionizing radiation. 
In one of its composition aspects, this invention is 
directed to pharmaceutical compositions for Selectively kill 
ing cells in a host bearing a tumor or atheroma comprising 
a pharmaceutically acceptable carrier and an effective 
amount of an agent that catalyzes the production of one or 
more reactive oxygen Species from an intracellular reducing 
agent provided that Said agent is not a teXaphyrin. 
In another of its composition aspects, the invention 
encompasses an agent that preferentially accumulates in 
tumor or atheroma cells and catalyzes the production of one 
or more reactive oxygen Species from a cellular metabolite 
having a Standard biochemical reduction potential more 
negative than the Standard biochemical reduction of oxygen/ 
hydrogen peroxide, a Source or precursor of the cellular 
metabolite, and a pharmaceutically acceptable excipient. 
Still further, this invention provides for use of an agent 
that catalyzes the production of one or more reactive oxygen 
Species from an intracellular reducing agent in the treatment 
of mammalian tumors or atheroma. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1-6 illustrate the rate of NADPH oxidation versus 
NADPH concentration by various metal cation complexes of 
a texaphyrin. 
FIG. 7 illustrates the rate of ascorbate oxidation versus 
ascorbate concentration in the presence of GdTeX. 
FIG. 8 illustrates the quantity of hydrogen peroxide 
generated by the addition of LuTex to NADPH as compared 
to control or to a LuTeX/NADPH Solution further containing 
catalase. 
FIG. 9 illustrates the quantity of hydrogen peroxide 
generated by the addition of GdTeX to ascorbate as com 
pared to control. 
FIG. 10 illustrates the percent survival of MES-SAhuman 
uterine cells in the presence of varying concentrations of 
ascorbate and varying concentrations of GdTeX. 
FIG. 11 illustrates the percent survival of MES-SA human 
uterine cells in the presence of varying concentrations of 
ascorbate and varying concentrations of LuTeX. 
FIG. 12 illustrates the percent survival of EMT-6 mouse 
mammary Sarcoma cells in the presence of varying concen 
trations of NADPH and varying concentrations of LuTex. 
FIG. 13 illustrates the percent survival of EMT-6 mouse 
mammary Sarcoma cells in the presence of varying concen 
trations of NADPH and varying concentrations of GdTex. 
FIG. 14 illustrates the percent survival of MES-SAhuman 
uterine cells in the presence of varying concentrations of 
GdTeX and BSO. 
FIG. 15 illustrates a proposed mechanism to explain the 
production of reactive oxygen Species by motexafin gado 












FIG. 16 illustrates the rate of NADPH oxidation versus 
time by various metal cation complexes of a teXaphyrin. 
FIGS. 17A and 17B illustrates the percent survival of 
MES-SA human uterine cells with ionizing radiation and 
varying concentrations of GdTeX, in the absence and the 
presence of BSO, respectively. 
FIG. 18 illustrates the clonogenic survival of MES-SA 
human uterine cells with ionizing radiation in the presence 
of GdTeX and/or BSO. 
FIG. 19 illustrates the percent Survival of MES-SA human 
uterine cells treated with BSO followed by varying concen 
trations of GdTex and Antimycins A. 
DETAILED DESCRIPTION OF THE 
INVENTION 
This invention is directed to novel methods for treating 
atheroma, tumors and other neoplastic tissue as well as other 
conditions that are responsive to the induction of targeted 
oxidative StreSS. However, prior to discussing this invention 
in further detail, the following terms will first be defined. 
The term “teXaphyrin refers to aromatic pentadentate 
macrocyclic “expanded porphyrins' which are considered as 
being an aromatic benzannulene containing both 18 at and 22 
JL-electron delocalization pathwayS. Such texaphryins and 
their synthesis are well known in the art.' Preferably, the 
teXaphyrins encompass any and all texaphyrin compounds 
disclosed by Magda, et al.'', Young, et al., Sessier, et al.''' 
and Hemmi, et al.' 
Particularly preferred texaphyrins include those repre 
sented by formula I: 
wherein M is a divalent metal cation or a trivalent metal 
cation; 
R" to R' as well as R7 and Rare independently selected 
from the group consisting of hydrogen, carboxyl, 
carboxylalkyl, acyl, acylamino, aminoacyl, alkyl, Substi 
tuted alky (particularly hydroxyalkyl or aminoalkyl, and 
especially where R is hydroxypropyl or aminopropyl), 
alkenyl, Substituted alkenyl, alkoxy, Substituted alkoxy, aryl, 
heteroaryl, heterocyclic, halo, hydroxyl, nitro, and a Saccha 
ride; 
R and R are independently selected from the group 
consisting of hydrogen, carboxyl, carboxylalkyl, acyl, 
acylamino, aminoacyl, alkyl, Substituted alkyl other than 
iodoalkyl, alkenyl, Substituted alkenyl, alkoxy, Substituted 
alkoxy, aryl, heteroaryl, heterocyclic, halo other than iodo, 
hydroxyl, nitro, and a Saccharide; 
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R and R' to R', are independently selected from the 
group consisting of hydrogen, alkyl, Substituted alkyl, 
alkoxy, Substituted alkoxy, carboxyl, carboxylalkyl, acyl and 
acylamino; and 
the charge, Z, is an integer having a value less than or 
equal to 5. 
The divalent or trivalent metal M is preferably selected 
from the group consisting of Ca(II), Mn(II), Co(II), Ni(II), 
Zn(II), Cd(II), Hg(II), Fe(II), Sm(II), UO(II), Mn(III), 
Co(III), Ni(III), Fe(III), Ho(III), Ce(III), Y(III), ln(III), 
Pr(III), Nd(III), Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), 
Er(III), Tm(III), Yb(III), Lu(III), La(III), and U(III). 
Particularly preferred texaphyrin compounds are repre 
sented by formula II: 
Even more preferred texaphyrin compounds are those of 
formula II wherein 
A. M is Gd(III) and Z is +2; 
B. M is Dy(III) and Z is +2; 
C. M is Y(III) and Z is +2; 
D. M is Lu(III) and Z is +2, 
E. M is Co(II) and Z is +1; 
F. M is Fe(III) and Z is +2; 
G. M is Eu(III) and Z is +2; 
H. M is Sm(III) and Z is +2; 
The term “alkyl” refers to a monoradical branched or 
unbranched Saturated hydrocarbon chain preferably having 
from 1 to 40 carbon atoms, more preferably 1 to 10 carbon 
atoms, and even more preferably 1 to 6 carbon atoms. This 
term is exemplified by groupS Such as methyl, ethyl, 
n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, n-decyl, 
tetradecyl, and the like. 
The term “substituted alkyl” refers to an alkyl group as 
defined above, having from 1 to 5 Substituents, and prefer 
ably 1 to 3 Substituents, Selected from the group consisting 
of alkoxy, Substituted alkoxy, cycloalkyl, Substituted 
cycloalkyl, cycloalkenyl, Substituted cycloalkenyl, acyl, 
acylamino, acyloxy, amino, Substituted amino, aminoacyl, 
aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, 







thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, 
thioalkoxy, Substituted thioalkoxy, aryl, aryloxy, heteroaryl, 
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, 
alkoxyamino, nitro, SO-alkyl, -SO-substituted alkyl, 
-SO-aryl, -SO-heteroaryl, -SO-alkyl, -SO 
substituted alkyl, -SO-aryl and -SO-heteroaryl. 
The term “alkylene' refers to a diradical of a branched or 
unbranched Saturated hydrocarbon chain, preferably having 
from 2 to 6 carbon atoms, more preferably 2 to 4 carbon 
atoms. This term is exemplified by groupS. Such as ethylene 
(-CH2CH2-), the propylene isomers (e.g., 
-CHCHCH-and-CH(CH)CH-) and the like. 
The term “substituted alkylene' refers to an alkylene 
group, as defined above, having from 1 to 5 Substituents, and 
II 
preferably 1 to 3 Substituents, Selected from the group 
consisting of alkoxy, Substituted alkoxy, cycloalkyl, Substi 
tuted cycloalkyl, cycloalkenyl, Substituted cycloalkenyl, 
acyl, acylamino, acyloxy, amino, Substituted amino, 
aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, 
halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, 
thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, 
thioalkoxy, Substituted thioalkoxy, aryl, aryloxy, heteroaryl, 
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, 
alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, 
-SO-aryl, -SO-heteroaryl, -SO-alkyl, -SO 
substituted alkyl, -SO-aryl and -SO-heteroaryl. 
Additionally, Such Substituted alkylene groups include those 
where 2. Substituents on the alkylene group are fused to form 
one or more cycloalkyl, Substituted cycloalkyl, 
cycloalkenyl, Substituted cycloalkenyl, aryl, heterocyclic or 
heteroaryl groups fused to the alkylene group. Preferably 
Such fused groups contain from 1 to 3 fused ring structures. 
The term “alkoxy” refers to the groups alkyl-O-, 
alkenyl-O-, cycloalkyl-O-and cycloalkenyl-O-, where 
alkyl, alkenyl, cycloalkyl, and cycloalkenyl are as defined 
herein. Preferred alkoxy groups are alkyl-O-and include, 
by way of example, methoxy, ethoxy, n-propoxy, iso 
propoxy, n-butoxy, tert-butoxy, Sec-butoxy, n-pentoxy, 
n-heXOXy, 1,2-dimethylbutoxy, and the like. 
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The term “substituted alkoxy' refers to the groups Sub 
stituted alkyl-O-, substituted alkenyl-O-, substituted 
cycloalkyl-O-and substituted cycloalkenyl-O-, where 
Substituted alkyl, Substituted alkenyl, Substituted cycloalkyl, 
and Substituted cycloalkenyl are as defined herein. A pre 
ferred class of Substituted alkoxy are polyoxyalkylene 
groups represented by the formula-O(R'O).R" where R is 
an alkylene group or a Substituted alkylene group, R is 
Selected from the group consisting of hydrogen, alkyl or 
substituted alkyl and q is an integer from 1 to 10. Preferably, 
in Such groups, q is from 1 to 5 and most preferably 3. 
The term “alkenyl refers to a monoradical of a branched 
or unbranched unsaturated hydrocarbon group preferably 
having from 2 to 40 carbon atoms, more preferably 2 to 10 
carbon atoms and even more preferably 2 to 6 carbon atoms 
and having at least 1 and preferably from 1-6 sites of vinyl 
unsaturation. Preferred alkenyl groups include ethenyl 
(-CH=CH-), n-propenyl (-CH-CH=CH-), iso-propenyl 
(-C(CH)=CH-), and the like. 
The term “substituted alkenyl refers to an alkenyl group 
as defined above having from 1 to 5 Substituents, and 
preferably 1 to 3 Substituents, Selected from the group 
consisting of alkoxy, Substituted alkoxy, cycloalkyl, Substi 
tuted cycloalkyl, cycloalkenyl, Substituted cycloalkenyl, 
acyl, acylamino, acyloxy, amino, Substituted amino, 
aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, 
halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, 
thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, 
thioalkoxy, Substituted thioalkoxy, aryl, aryloxy, heteroaryl, 
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, 
alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, 
-SO-aryl, -SO-heteroary 1, -SO-alkyl, -SO 
substituted alkyl, -SO-aryl and -SO-heteroaryl. 
The term “acyl” refers to the groups HC(O), alkyl-C 
(O), Substituted alkyl-C(O), cycloalkyl-C(O)O-, Sub 
stituted cycloalkyl-C(O), cycloalkenyl-C(O), substi 
tuted cycloalkenyl-C(O), aryl-C(O), heteroaryl-C(O)- 
and heterocyclic-C(O)-where alkyl, substituted alkyl, 
cycloalkyl, Substituted cycloalkyl, cycloalkenyl, Substituted 
cycloalkenyl, aryl, heteroaryland heterocyclic are as defined 
herein. 
The term “acylamino” refers to the group -C(O)NRR 
where each R is independently hydrogen, alkyl, Substituted 
alkyl, aryl, heteroaryl, heterocyclic or where both R groups 
are joined to form a heterocyclic group (e.g., morpholino) 
wherein alkyl, Substituted alkyl, aryl, heteroaryl and hetero 
cyclic are as defined herein. 
The term "aminoacyl” refers to the group -NRC(O)R 
where each R is independently hydrogen, alkyl, Substituted 
alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, Sub 
Stituted alkyl, aryl, heteroaryland heterocyclic are as defined 
herein. 
The term “aminoacyloxy” refers to the group -NRC(O) 
OR where each R is independently hydrogen, alkyl, Substi 
tuted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, 
Substituted alkyl, aryl, heteroaryl and heterocyclic are as 
defined herein. 
The term “acyloxy” refers to the groups alkyl-C(O)O-, 
substituted alkyl-C(O)O-, cycloalkyl-C(O)O-, substi 
tuted cycloalkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O) 
O-, and heterocyclic-C(O)O-wherein alkyl, substituted 
alkyl, cycloalkyl, Substituted cycloalkyl, aryl, heteroaryl, 
and heterocyclic are as defined herein. 
The term “aryl” refers to an unsaturated aromatic car 
bocyclic group of from 6 to 20 carbon atoms having a single 
ring (e.g., phenyl) or multiple condensed (fused) rings (e.g., 
naphthyl or anthryl). Preferred aryls include phenyl, naph 











Unless otherwise constrained by the definition for the aryl 
Substituent, Such aryl groups can optionally be Substituted 
with from 1 to 5 substituents, preferably 1 to 3 substituents, 
Selected from the group consisting of acyloxy, hydroxy, 
thiol, acyl, alkyl, alkoxy, alkenyl, cycloalkyl, cycloalkenyl, 
Substituted alkyl, Substituted alkoxy, Substituted alkenyl, 
Substituted cycloalkyl, Substituted cycloalkenyl, amino, Sub 
Stituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, 
aZido, carboxyl, carboxylalkyl, cyano, halo, nitro, 
heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, 
aminoacyloxy, oxyacylamino, thioalkoxy, Substituted 
thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, 
-SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, 
-SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO 
heteroaryl and trihalomethyl. Preferred aryl Substituents 
include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and 
thioalkoxy. 
The term “aryloxy' refers to the group aryl-O-wherein 
the aryl group is as defined above including optionally 
Substituted aryl groupS as also defined above. 
The term “amino” refers to the group -NH. 
The term “substituted amino refers to the group -NRR 
where each R is independently Selected from the group 
consisting of hydrogen, alkyl, Substituted alkyl, cycloalkyl, 
Substituted cycloalkyl, alkenyl, Substituted alkenyl, 
cycloalkenyl, Substituted cycloalkenyl, aryl, heteroaryl and 
heterocyclic provided that both R's are not hydrogen. 
The term “carboxyalkyl” refers to the groups “-C(O)O- 
alkyl”, “-C(O)O-substituted alkyl”, “-C(O)O- 
cycloalkyl”, “-C(O)O-substituted cycloalkyl”, “-C(O)O- 
alkenyl', and "-CO)O-substituted alkenyl', where alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
and Substituted alkenyl, are as defined herein. 
The term “cycloalkyl” refers to cyclic alkyl groups of 
from 3 to 20 carbon atoms having a single cyclic ring or 
multiple condensed rings. Such cycloalkyl groups include, 
by way of example, Single ring Structures Such as 
cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the 
like, or multiple ring Structures Such as adamantanyl, and the 
like. 
The term “substituted cycloalkyl” refers to cycloalkyl 
groups having from 1 to 5 Substituents, and preferably 1 to 
3 Substituents, Selected from the group consisting of alkoxy, 
Substituted alkoxy, cycloalkyl, Substituted cycloalkyl, 
cycloalkenyl, Substituted cycloalkenyl, acyl, acylamino, 
acyloxy, amino, Substituted amino, aminoacyl, 
aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, 
hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, 
thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, 
thioalkoxy, Substituted thioalkoxy, aryl, aryloxy, heteroaryl, 
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, 
alkoxyamino, nitro, SO-alkyl, -SO-substituted alkyl, 
-SO-aryl, -SO-heteroaryl, -SO-alkyl, -SO 
substituted alkyl, -SO-aryl and -SO-heteroaryl. 
The term “cycloalkenyl refers to cyclic alkenyl groups of 
from 4 to 20 carbon atoms having a single cyclic ring and at 
least one point of internal unsaturation. Examples of Suitable 
cycloalkenyl groups include, for instance, cyclobut-2-enyl, 
cyclopent-3-enyl, cyclooct-3-enyl and the like. 
The term “substituted cycloalkenyl' refers to cycloalk 
enyl groups having from 1 to 5 Substituents, and preferably 
1 to 3 Substituents, Selected from the group consisting of 
alkoxy, Substituted alkoxy, cycloalkyl, Substituted 
cycloalkyl, cycloalkenyl, Substituted cycloalkenyl, acyl, 
acylamino, acyloxy, amino, Substituted amino, aminoacyl, 
aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, 
hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, 
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thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, 
thioalkoxy, Substituted thioalkoxy, aryl, aryloxy, heteroaryl, 
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, 
alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, 
-SO-aryl, -SO-heteroary 1, -SO-alkyl, -SO 
substituted alkyl, -SO-aryl and -SO-heteroaryl. 
The term “halo” or “halogen” refers to fluoro, chloro, 
bromo and iodo. 
The term “heteroaryl” refers to an aromatic group of from 
1 to 15 carbon atoms and 1 to 4 heteroatoms selected from 
oxygen, nitrogen and Sulfur within at least one ring (if there 
is more than one ring). 
Unless otherwise constrained by the definition for the 
heteroaryl Substituent, Such heteroaryl groups can be option 
ally substituted with 1 to 5 substituents, preferably 1 to 3 
Substituents, Selected from the group consisting of acyloxy, 
hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, cycloalkyl, 
cycloalkenyl, Substituted alkyl, Substituted alkoxy, Substi 
tuted alkenyl, Substituted cycloalkyl, Substituted 
cycloalkenyl, amino, Substituted amino, aminoacyl, 
acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, 
carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, 
heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, 
thioalkoxy, Substituted thioalkoxy, thio aryloxy, 
thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, 
-SO-aryl, -SO-heteroary 1, -SO-alkyl, -SO 
substituted alkyl, -SO-aryl, -SO-heteroaryl and triha 
lomethyl. Preferred aryl Substituents include alkyl, alkoxy, 
halo, cyano, nitro, trihalomethyl, and thioalkoxy. Such het 
eroaryl groups can have a single ring (e.g., pyridyl or furyl) 
or, multiple condensed rings (e.g., indolizinyl or 
benzothienyl). Preferred heteroaryls include pyridyl, pyrro 
lyl and furyl. 
The term "heteroaryloxy' refers to the group heteroaryl 
O-. 
The term “heterocycle” or "heterocyclic” refers to a 
monoradical Saturated unsaturated group having a single 
ring or multiple condensed rings, from 1 to 40 carbon atoms 
and from 1 to 10 hetero atoms, preferably 1 to 4 
heteroatoms, Selected from nitrogen, Sulfur, phosphorus, 
and/or oxygen within the ring. 
Unless otherwise constrained by the definition for the 
heterocyclic Substituent, Such heterocyclic groups can be 
optionally substituted with 1 to 5, and preferably 1 to 3 
Substituents, Selected from the group consisting of alkoxy, 
Substituted alkoxy, cycloalkyl, Substituted cycloalkyl, 
cycloalkenyl, Substituted cycloalkenyl, acyl, acylamino, 
acyloxy, amino, Substituted amino, aminoacyl, 
aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, 
hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, 
thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, 
thioalkoxy, Substituted thioalkoxy, aryl, aryloxy, heteroaryl, 
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, 
alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, 
-SO-ary 1,-SO-hetero aryl, -SO-alkyl, -SO,- 
substituted alkyl, -SO-aryl and -SO-heteroaryl. Such 
heterocyclic groups can have a single ring or multiple 
condensed rings. Preferred heterocyclics include 
morpholino, piperidinyl, and the like. 
Examples of nitrogen heterocycles and heteroaryls 
include, but are not limited to, pyrrole, imidazole, pyrazole, 
pyridine, pyrazine, pyrimidine, pyridazine, indolizine, 
iso indole, indole, in dazole, purine, quinolizine, 
isoquinoline, quinoline, phthalazine, naphthylpyridine, 
quinoxaline, quinazoline, cinnoline, pteridine, carbazole, 
carboline, phenanthridine, acridine, phenanthroline, 











phenothiazine, imidazolidine, imidazoline, piperidine, 
pipe razine, indoline, morpholino, pipe ridinyl, 
tetrahydrofuranyl, and the like as well as N-alkoxy-nitrogen 
containing heterocycles. 
The term "heterocyclooxy” refers to the group 
heterocyclic-O-. 
The term “thioheterocyclooxy' refers to the group 
heterocyclic-S-. 
The term “oxyacylamino” refers to the group -OC(O) 
NRR where each R is independently hydrogen, alkyl, Sub 
Stituted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, 
Substituted alkyl, aryl, heteroaryl and heterocyclic are as 
defined herein. 
The term “thiol” refers to the group -SH. 
The term “thioalkoxy” refers to the group -S-alkyl. 
The term “substituted thioalkoxy' refers to the group 
-S-Substituted alkyl. 
The term “thioaryloxy' refers to the group aryl-S- 
wherein the aryl group is as defined above including option 
ally Substituted aryl groups also defined above. 
The term “thioheteroaryloxy' refers to the group 
heteroaryl-S- wherein the heteroaryl group is as defined 
above including optionally Substituted aryl groups as also 
defined above. 
The term "saccharide” refers to oxidized, reduced or 
Substituted Saccharides hexoses Such as D-glucose, 
D-mannose, D-xylose, D-galactose, D-glucuronic acid, 
N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, Sialyic 
acid, iduronic acid, L-fucose, and the like, pentoses Such as 
D-ribose or D-arabinose, ketoses such as D-ribulose or 
D-fructose; disaccharides Such as Sucrose, lactose, or mal 
tose, derivatives Such as acetals, amines, acylated, Sulfated 
and phosphorylated Sugars, oligosaccharides having from 2 
to 10 Saccharide units. For the purposes of this definition, 
these Saccharides are referenced using conventional three 
letter nomenclature and the Saccharides can be either in their 
open or preferably in their pyranose form. 
AS to any of the above groups that contain one or more 
Substituents, it is understood, of course, that Such groups do 
not contain any Substitution or Substitution patterns which 
are Sterically impractical and/or Synthetically non-feasible. 
In addition, the compounds of this invention include all 
Stereochemical isomers and mixtures thereof arising from 
the Substitution of these compounds. 
The term “treatment” or “treating” means any treatment 
of a disease in a mammal, including: 
(i) preventing the disease, that is, causing the clinical 
Symptoms of the disease not to develop; 
(ii) inhibiting the disease, that is, arresting the develop 
ment of clinical Symptoms, and/or 
(iii) relieving the disease, that is, causing the regression of 
clinical Symptoms. 
The term “effective amount” means a dosage sufficient to 
provide treatment for the disease State being treated. This 
will vary depending on the patient, the disease and the 
treatment being effected. 
The term “pharmaceutically acceptable salt” refers to salts 
derived from a variety of organic and inorganic counter ions 
well known in the art and include, by way of example only, 
Sodium, potassium, calcium, magnesium, ammonium, 
tetraalkylammonium, and the like; and when the molecule 
contains a basic functionality, Salts of organic or inorganic 
acids, Such as hydrochloride, hydrobromide, tartrate, 
meSylate, acetate, maleate, oxalate and the like. 
The term “cellular metabolite” or “reducing metabolite” 
refers to a compound found naturally within a living cell. 
The cellular metabolites employed to generate reactive 
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oxygen Species by the methods disclosed herein having a 
Standard biochemical reduction potential more negative than 
the Standard biochemical reduction potential of oxygen/ 
hydrogen peroxide. Such metabolites include, by way of 
example only, NAD(P)H (i.e., NADPH and/or NADH), 
FADH2, ascorbate, reduced glutathione, dihydrolipoic acid 
and the like. 
The term “standard biochemical reduction potential” 
refers to the reduction potential of a metabolite measured at 
pH 7 and 25 C. in an aqueous Solution. At these conditions, 
oxygen and hydrogen peroxide have a reduction potential of 
approximately 0.273 V.' 
The term “thiol-depleting compound” refers to a com 
pound which upon administration to a host or to a cell, 
results in a global lowering of the concentration of available 
reduced thiol (e.g., glutathione). Examples of thiol-depleting 
compounds include buthionine sulfoximine (“BSO", a 
known inhibitor of glutathione Synthesis), diethyl maleate (a 
thiol reactive compound) dimethyl fumarate, N-ethyl 
maleimide, diamide (diazene dicarboxylic acid bis-(N,N'- 
dimethylamide)) and the like. 
The term "ionizing radiation” refers to radiation conven 
tionally employed in the treatment of tumors which 
radiation, either as a large Single dosage or as repeated 
Smaller dosages, will initiate ionization of water thereby 
forming reactive oxygen Species. Ionizing radiation 
includes, by way of example, X-rays, electron beams, Y-rayS, 
and the like. 
The term “porphyrin derivative” refers to those molecules 
which contain as part of their chemical Structure a polypyr 
role macrocycle. 
The term “DNA alkylators' refer to well known alkylat 
ing agents which alkylate DNA thereby interfering with 
cellular processes and leading to cell death. Suitable alky 
lating agents include nitrogen mustards (e.g., 
mechlorethamine, cyclophosphamide, ifosfamide, 
mephalan, chlorambucil and estramustine), etheleneimines 
and methylmelamines (e.g., hexamethylmelamine and 
thiotepa), alkyl Sulfonates (e.g., buSulfan), nitroureas (e.g., 
carmustine, lomusine, Semustine, and Streptozocin), and 
triazines (e.g., dacarbazine, procarbazine, and aziridine). 
The term “topoisomerase” refers to enzymes that control 
and modify the topological States of DNA by catalyzing the 
concerted breaking and rejoining of DNA strands. (See, for 
example, D'Arpa et al., Biochim. Biophys. Acta, 989, 163 
(1989). At least two distinct topoisomerases are known in 
the art and are designated as topoisomerase I and II. 
The term “topoisomerase inhibitors' refers to compounds 
which in vivo inhibit one or more of the topoisomerase 
enzymes. Topoisomerase II inhibitors are well known in the 
art and include, by way of example, etoposide (VP-16), 
teniposide (VM-26), mitoxantrone, m-AMSA, adriamycin 
(doxorubicin), ellipticine and daunomycin. Topoisomerase I 
inhibitors are also well known in the art and include, for 
example, camptothecin and Hoechst 33342. See, for 
instance, Allan Y. Chen, et al., “A New Mammalian DNA 
Topoisomerase I Poison Hoechst 33342: Cytoxicity and 
Drug Resistance in Human Cell Cultures”, Cancer Research, 
53:1332–1337 (1993). Still other topoisomerase I and II 
inhibitors are disclosed in U.S. Pat. No. 5,807,874; by 
Darshan Makhey, et al., “Coralyne and Related Compounds 
as Mammalian Topoisomerase I and Topoisomerase II 
Poisons”, Bioorg. & Med. Chem. Lett., 4:781-791, (1996) 
and Darshan Makhey, et al., “Protoberberine Alkaloids and 
Related Compounds as Dual Inhibitors of Mammalian 
Topoisomerase I and II”, Med. Chem. Res., 5:1-12(1994). 
All of these references are incorporated herein by reference 











The term “redox cycling agents' refers to compounds 
which may exist in two or more oxidation States and are able 
to lower the activation barrier for electron transfer between 
two compounds. Examples of Suitable redox cycling agents 
include, for instance, alloxan, phenazine methoSulfate, 
menadione, copper/putrescine/pyridine, methylene blue, 
paraquat, doxorubicin, bleomycin, and ruthenium (II) tris 
(1,10-phenanthroline-5,6-dione). 
The term “metabolic inhibitors' or “antimetabolites' refer 
to materials which interfere with the availability of one or 
more cellular metabolites such as ascorbate, NAD(P)H, etc. 
Such metabolic inhibitors are well known in the art and 
include, by way of example, folic acid analogs (e.g., meth 
otrexate and trimetrexate), pyrimidine analogs (e.g., 
fluorouracil, floxuridine, cytarabine and azacitidine), and 
purine analogs and related inhibitors (e.g., mercaptopurine, 
thioguanine, pentostatin and fludarabine). 
The term “mitochondrial inhibitors' refers to compounds 
that interfere with mitochondrial metabolism including, for 
example, oligomycin (a specific inhibitor of motochondrial 
ATP-ase, i.e., complex 5) and antimycins A (a complex 3 
inhibitor that blocks the conversion of ubiquinol to 
ubiquinone). 
Methods 
Compounds that display affinity for electrons can poten 
tiate the biological effect of ionizing radiation and, 
accordingly, may have use as radiation Sensitizers. The 
determination of which compounds displaying electron 
affinity may possess radiation Sensitization properties was 
heretofore not possible absent in Vivo trial and error testing. 
Indeed, motexafin gadolinium PCI-0120, XcytrinTM, 
GdTex, Formula II where M is Gd(III) is reported to 
enhance the efficacy of radiation in animal tumor models and 
is currently in Phase III clinical development as an adjuvant 
to radiation therapy.'" However, the related lutetium(III) 
congener (PCI-0123, LutrinTM, LuTex) in the same animal 
model did not possess Similar radiation Sensitization prop 
erties. These results have led us to explore the chemical 
mechanisms for the observed biological activity of GdTex. 
Biochemically, two cellular forms of rapidly accessible 
energy are maintained for metabolic use: high energy phos 
phoryl linkages e.g., phosphocreatine, ATP) and electron 
carriers, i.e., the cofactors NAD(P)H). Initially, texaphyrins 
were evaluated for their ability to alter cellular energy 
charge by catalyzing the hydrolysis of high energy phos 
phoryl linkages. The results of this evaluation Suggested 
Some apparent effect; however, the observed rate accelera 
tions Seemed incompatible with biological importance. 
Co-incubation of NADH or NADPH with texaphyrin 
derivatives, however, rapidly converted these cofactors to 
their oxidized forms, at catalytic concentrations of complex. 
Examination of texaphyrins containing different lanthanide 
ions showed that the observed oxidation rates measured by 
the amount of NADP+ formed correlated with Lewis acidity, 
whereas the transition metal derivatives displayed a lack of 
reactivity which is consistent with the fact that the redox 
potentials of texaphyrin complexes of divalent cations are 
about 200 mV more negative than those of the trivalent 
cations. It is also consistent with the lower attraction of 
oxygen anion ligands for transition metal cations than for 
lanthanide cations. The results of this examination are 
depicted in FIGS. 1-6. 
Without being limited to any theory, these findings Sug 
gested that the reaction proceeded via initial complexation 
of cofactor phosphoric anhydride with the metal center, 
followed by slow two-electron (or hydride) transfer to the 
teXaphyrin macrocycle. Indeed, the reaction displayed Satu 
ration kinetics. 
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The above Studies were conducted under aerobic condi 
tions. Replacement of oxygen with inert atmosphere led to 
rapid texaphyrin complex degradation, as evidenced by 
bleaching of the characteristic texaphyrin uV-Vis absorbance 
spectrum (data not shown). Again, without being limited to 
any theory, this led to the Supposition that oxygen might 
Serve as the ultimate electron acceptor under aerobic con 
ditions. 
AS illustrated in Examples 1-4 below, this Supposition 
was assessed by measuring the formation of oxidized spe 
cies or hydrogen peroxide upon incubation of the cellular 
metabolite NADPH with LuTex (Examples 1 and 3) or the 
cellular metabolite ascorbate with GdTex (Examples 2 and 
4). AS appropriate, the addition of catalase to the reaction 
mixture confirmed that the assay Signal generated therein 
was due to hydrogen peroxide. In each case, the cellular 
metabolites, NADPH and ascorbate, have a standard bio 
chemical reduction potential more negative than the Stan 
dard biochemical reduction of oxygen/hydrogen peroxide. 
These results evidenced that a compound's potential to 
exhibit radiation Sensitizing activity correlates to its ability 
to form one or more reactive oxygen Species from cellular 
metabolites which have a Standard biochemical reduction 
potential more negative than the Standard biochemical 
reduction of oxygen/hydrogen peroxide. In turn, this pro 
vides a facile method for testing a compounds radiation 
Sensiziting capacity by introducing the to-be tested com 
pound into an aqueous Solution comprising a cellular 
metabolite having a Standard biochemical reduction poten 
tial more negative than the Standard biochemical reduction 
potential of oxygen/hydrogen peroxide; monitoring the Solu 
tion for the occurrence of a reaction that produces one or 
more reactive oxygen species, and determining whether the 
compound has probable radiation Sensitization activity, 
wherein this activity correlates to the occurrence and extent 
of a reaction that produces reactive oxygen Species. 
AS is apparent, this assay can monitor any of a number of 
different components to assess the extent of the reaction. For 
example, the depletion of the cellular metabolite can be 
assayed; the production of an oxidized form of cellular 
metabolite can be assayed; the depletion of oxygen from the 
reaction Solution can be assayed; or the appearance of 
hydrogen peroxide can be assayed. Each of these assays can, 
in turn, be used to determine the extent of reaction. AS 
above, the cellular metabolite employed is one that has a 
Standard biochemical reduction potential more negative than 
the Standard biochemical reduction of oxygen/hydrogen 
peroxide. Such metabolites include, by way of example only, 
NADPH, NADH, FADH, ascorbate and reduced glu 
tathione. 
In a particularly preferred embodiment, compounds deter 
mined to have radiation Sensitization activity by virtue of 
their ability to generate one or more reactive oxygen Species 
in Vivo are useful as adjuncts to treating mammalian tumors 
by ionizing radiation. In this embodiment, the compound 
possessing radiation Sensitization activity is administered to 
the tumor in Sufficient quantities to therapeutically enhance 
the effect of ionizing radiation on tumor cell death. 
For example, the proliferation of human ovarian cancer 
cell line MES-SA" can be used to assess the degree of 
ascorbate and cofactor oxidation under cell culture condi 
tions. RPMI 1640, which contains no ascorbate, was used as 
the medium in these experiments. Specifically, as illustrated 
in Examples 3 and 4, coincubation of ascorbate and GdTeX 
or LuTeX resulted in decreased cell proliferation, as mea 
sured by tetrazolium salt (MTT) reduction,' due to hydro 











ascorbate, which parallel the dissociation constant values 
found. Similar results were obtained using NADPH as 
Substrate. 
Particularly useful radiation Sensitizers are compounds 
that preferentially localize in the tumors. For example, it is 
well known that texaphyrin and porphyrin compounds will 
preferentially localize in mammalian tumors and have 
potential radiation Sensitization activity. Similarly, other 
compounds determined to have radiation Sensitization activ 
ity may also preferentially localize in mammalian tumors or 
Such compounds can be derivatized to impart preferential 
localization in mammalian tumors. For example, Such com 
pounds can be derivatized by conventional Synthetic chemi 
cal techniques to append to a molecule which is known to 
localize in mammalian tumors. Such molecules include 
monoclonal antibodies directed to tumor antigens, 
teXaphyrins, porphyrins, peptides Such as disclosed by 
Urzgiris, et al., U.S. Pat. No. 5,762.909 which is incorpo 
rated herein by reference in its entirety, etc. Specific tech 
niques for coupling Such compounds are disclosed in U.S. 
patent application Ser. No. 09/431,298, filed Oct.29, 1999 
and entitled “Compounds for Treating Atheroma, Tumors 
and other Neoplastic TiSSue' which application is incorpo 
rated herein by reference in its entirety. 
One preferred compound for use as a radiation Sensitizer 
are porphyrin derivatives and, in particular, iron(III) por 
phyrin. Such derivatives are known to accumulate in tumor 
tissue and iron(III) porphyrin has been disclosed as gener 
ating hydrogen peroxide from ascorbate and oxygen." 
Alternatively, the generation of one or more reactive 
oxygen Species by the radiation Sensitizers of the present 
invention can be used by itself (or in conjunction with the 
administration of a reducing metabolite) to therapeutically 
treat a tumor or atheroma. When used in conjunction with 
the administration of Such reducing metabolites, the radia 
tion Sensitizers encompassed by the present invention 
exclude the cobalt and iron complexes of phthalocyanine 
and napthalocyanine. In one aspect of the invention, this can 
be particularly useful when the patient has been exposed to 
the maximum amount of ionizing radiation which can be 
tolerated by the patient. 
Further, the role of glutathione and ascorbate towards 
lesions induced by ionizing radiation has been well Stud 
ied.' it is generally accepted that a competition exists 
between these species and molecular oxygen for DNA 
lesions, Such that a protective role for glutathione (and, at 
low levels of glutathione, ascorbate) can be demonstrated 
under anoxic conditions. AS is known in the art, glutathione 
imparts a protective role by Virtue of a redox reaction 
wherein the free thiol group of glutathione is oxidized to 
form a disulfide linkage with a Second oxidized glutathione 
molecule. Accordingly, in order to limit the protection 
afforded by gluathione or other thiol containing 
antioxidants, this invention contemplates co-administraton 
of an effective amount of a thiol-depleting agent to the tumor 
cell or to a patient Suffering from cancer in order to reduce 
the amount of thiol containing antioxidants contained 
therein. Preferably the thiol-depleting agent is buthionine 
Sulfoximine. 
Alternatively, known chemotherapeutic agents or other 
agents which alter metabolic pathways can be 
co-administered with the radiation Sensitizing compound. 
Such agents include, by way of example, DNA alkylators, 
topoisomerase inhibitors, redox cycling agents, metabolic 
inhibitors and mitochondrial inhibitors. 
The metabolic balance of a cell entails numerous Syn 
chronous reactions. FIG. 15 illustrates pathways entailing 
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the cellular metabolites ascorbate and NADPH, both of 
which have a Standard biochemical reduction potential more 
negative than the Standard biochemical reduction potential 
of oxygen/hydrogen peroxide. Agents capable of catalyzing 
the production of one or more reactive oxygen Species from 
either or both of these cellular metabolites can drive the cell 
toward a State of oxidative StreSS. Also illustrated are certain 
of the effects of ionizing radiation, e.g., leading to the 
generation of hydroxyl radicals and additional hydrogen 
peroxide. Employing the methods of the present invention, 
it has been determined that motexafin gadolinium catalyzes 
the production of hydrogen peroxide from ascorbate to a 
much greater extent than does motexafin lutetium, whereas 
the converse is true with respect to NADPH. This suggests 
the co-administration of motexafin gadolinium and moteXa 
fin lutetium to drive both of these pathways as a means of 
increasing oxidative StreSS to increase a cell's Sensitivity to 
radiation. 
The preferred pharmaceutical compositions and methods 
of treatment of the present invention include the following: 
Co-administration of a texaphyrin and a thiol-depleting 
agent, a reducing metabolite or Source thereof, or a 
mitochondrial inhibitor, with or without ionizing radia 
tion. 
Co-administration of a texaphyrin and a thiol-depleting 
agent, with or without ionizing radiation; particularly 
where the thiol-depleting agent is BSO and most pref 
erably with ionizing radiation. Especially preferred are 
the co-administration of a thiol-depleting agent with 
GdTex, CoTex, the mu-oxo dimer of iron texaphyrin 
(“Fe(Tex)O”), EuTex, SmTex, di-amino GdTex and 
di-amino LuTeX, again, more preferably where the 
thiol-depleting agent is BSO and most preferably with 
ionizing radiation. The co-adminstration of GdTeX and 
BSO, followed by administration of ionizing radiation, 
is most preferred. 
Co-administration of a teXaphyrin and a reducing metabo 
lite or Source thereof, with or without ionizing 
radiation, particularly where the teXaphyrin is 
co-administered with ascorbate. Especially preferred 
are the co-administration of a reducing metabolite with 
GdTex, CoTex, the mu-oxo dimer of iron texaphyrin 
(“Fe(Tex)'), EuTex, SmTex, di-amino GdTex and 
di-amino LuTeX, again, more preferably where the 
reducing metabolite is ascorbate and most preferably 
with ionizing radiation. The co-adminstration of GdTex 
and ascorbate, followed by administration of ionizing 
radiation, is most preferred. 
Co-administration a texaphyrin (particularly GdTex), 
BSO and ascorbate, with or without ionizing radiation, 
and most preferably followed by ionizing radiation. 
Co-administraton of a non-texaphyrin compound that 
catalyzes the production of one or more reactive oxy 
gen species from a cellular metabolite having a Stan 
dard biochemical reduction potential more negative 
than the Standard biochemical reduction of oxygen/ 
hydrogen peroxide and ionizing radiation. 
Co-administration of a DNA alkylator, thiol-depleting 
agent, topoisomerase inhibitor, redox cycling agent, 
metabolic inhibitor and/or mitochondrial inhibitor and 
a non-texaphyrin compound that catalyzes the produc 
tion of one or more reactive oxygen Species from a 
cellular metabolite having a Standard biochemical 
reduction potential more negative than the Standard 
biochemical reduction of oxygen/hydrogen peroxide, 











acid with cobalt or iron phthalocyanines and naphtha 
locyanines without ionizing radiation). 
Co-administration of a redox cycling agent and a non 
teXaphyrin compound that catalyzes the production of 
one or more reactive oxygen Species from a cellular 
metabolite having a Standard biochemical reduction 
potential more negative than the Standard biochemical 
reduction of oxygen/hydrogen peroxide, with or with 
out ionizing radiation, particularly where the redox 
cycling agent is doxorubicin or bleomycin, and most 
particularly with ionizing radiation. Especially pre 
ferred is the non-texaphyrin compound methylene blue, 
co-administered with bleomycin or doxorubicin, and 
without ionizing radiation. 
Excluded from the pharmaceutical compositions and 
methods of treatment of the present invention are those 
combinations of texaphyrins (such as motexafin 
gadolinium), chemotherapeutic agents (Such as doxorubicin) 
and/or co-therapeutic agents (such as ionizing, photody 
namic and Sonodynamic energy sources) previously 
disclosed, for example, in U.S. Pat. No. 5,776,925 and in 
WO00/01414. However, to the extent that pharmacologi 
cally active mediators of oxidative StreSS have not previ 
ously been disclosed for administration in combination with 
a texaphyrin, Such as thiol-depleting agents (especially 
BSO), mitochondrial inhibitors (such as antimycins A) and 
certain redox cycling agents (e.g., excluding doxorubicin) 
are intended to be within the scope of the invention. Simi 
larly excluded is the co-administration of ascorbic acid with 
cobalt or iron phthalocyanines and naphthalocyanines (e.g., 
as disclosed in U.S. Pat. No. 6,004,953), but, not when 
combined with the administration of ionizing radiation. 
Utility 
Methods for determining compounds which are useful as 
radiation Sensitizers provide a facile means to assess the 
potential of Such compound for use as adjuncts in treating 
tumors with ionizing radiation. In addition, the fact that Such 
compounds produce one or more reactive oxygen Species in 
vivo dictates that these compounds will be useful in their 
own right in killing cells Such as tumor cells even in the 
absence of ionizing radiation. 
When employed with ionizing radiation, the amount of 
compound administered to the patient will vary depending 
upon what is being administered, the purpose of the 
administration, the State of the patient, the manner of 
administration, and the like. In particular, a Sufficient 
amount of the compound is administered to the cell or to the 
patient to therapeutically enhance the effect of ionizing 
radiation on tumor cell death. An amount adequate to 
accomplish this is defined as “therapeutically effective 
dose.” Amounts effective for this use will depend on the 
judgment of the attending clinician depending upon factors 
Such as the degree or Severity of the cancer in the patient, the 
age, weight and general condition of the patient, and the like. 
Preferably, radiation Sensitizing compounds used in con 
junction with ionizing radiation are administered at dosages 
ranging from about 0.1 to about 100 mg/kg/day. Preferably, 
the active agent is administered approximately 2–5 hours 
prior to exposure to ionizing radiation. 
When employed in the absence of ionizing radiation, the 
amount of compound administered to the patient will again 
vary depending upon what is being administered, the pur 
pose of the administration, the State of the patient, the 
manner of administration, and the like. In particular, a 
Sufficient amount of the compound is administered to the cell 
or to the patient So as to generate reactive oxygen Species in 
quantities effective to initiate tumor cell death. An amount 
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adequate to accomplish this is defined as “therapeutically 
effective dose.” Amounts effective for this use will depend 
on the judgment of the attending clinician depending upon 
factorS Such as the degree or Severity of the cancer in the 
patient, the age, weight and general condition of the patient, 
and the like. Preferably, when So employed, the compound 
is administered at dosages ranging from about 0.1 to about 
100 mg/kg/day. 
Similarly, drugs co-administered to the patient Such as 
DNA alkylators, topoisomerase inhibitors, redox cycling 
agents, thiol-depleting agents and metabolic inhibitors are 
also employed in Sufficient quantities for their intended 
purpose. These amounts are well documented in the art. 
AS noted above, the compounds administered to a patient 
are in the form of pharmaceutical compositions described 
herein. These compositions may be Sterilized by conven 
tional Sterilization techniques, or may be Sterile filtered. 
When aqueous Solutions are employed, these may be pack 
aged for use as is, or lyophilized, the lyophilized preparation 
being combined with a Sterile aqueous carrier prior to 
administration. The pH of the compound preparations typi 
cally will be between 3 and 11, more preferably from 5-9 
and most preferably from 7 and 8. It will be understood that 
use of certain of the foregoing excipients, carriers, or Sta 
bilizers will result in the formation of pharmaceutical Salts. 
Pharmaceutical Formulations 
When employed as pharmaceuticals, compounds 
described herein are usually administered in the form of 
pharmaceutical compositions. These compounds can be 
administered by a variety of routes including oral, 
intravenous, intramuscular, and the like. These compounds 
are effective as both injectable and oral compositions. Such 
compositions are prepared in a manner well known in the 
pharmaceutical art and comprise at least one active com 
pound. 
These pharmaceutical compositions contain, as the active 
ingredient, one or more of the compounds described herein 
asSociated with pharmaceutically acceptable carriers. In 
making these compositions, the active ingredient is usually 
mixed with an excipient. When the excipient Serves as a 
diluent, it can be a Solid, Semi-Solid, or liquid material, 
which acts as a vehicle, carrier or medium for the active 
ingredient. Thus, the compositions can be in the form of 
tablets, pills, elixirs, Suspensions, emulsions, Solutions, 
Syrups, and the like containing, for example, up to 10% by 
weight of the active compound, Soft and hard gelatin 
capsules, Sterile injectable Solutions, and Sterile packaged 
powders. 
In preparing a formulation, it may be necessary to mill the 
active compound to provide the appropriate particle size 
prior to combining with the other ingredients. If the active 
compound is Substantially insoluble, it ordinarily is milled to 
a particle size of less than 200 mesh. If the active compound 
is Substantially water Soluble, the particle Size is normally 
adjusted by milling to provide a Substantially uniform dis 
tribution in the formulation, e.g. about 40 mesh. 
Some examples of Suitable excipients include lactose, 
dextrose, Sucrose, Sorbitol, mannitol, Starches, gum acacia, 
calcium phosphate, alginates, tragacanth, gelatin, calcium 
Silicate, microcrystalline cellulose, polyvinylpyrrolidone, 
cellulose, Sterile water, Syrup, and methyl cellulose. The 
formulations can additionally include: lubricating agents 
Such as talc, magnesium Stearate, and mineral oil; wetting 
agents, emulsifying and Suspending agents, preserving 
agents Such as methyl- and propylhydroxy-benzoates, 
Sweetening agents, and flavoring agents. The compositions 











Sustained or delayed release of the active ingredient after 
administration to the patient by employing procedures 
known in the art. 
The compositions are preferably formulated in a unit 
dosage form, each dosage containing from about 5 to about 
100 mg, more usually about 10 to about 30 mg, of the active 
ingredient. The term “unit dosage forms' refers to physically 
discrete units Suitable as unitary dosages for human Subjects 
and other mammals, each unit containing a predetermined 
quantity of active material calculated to produce the desired 
therapeutic effect, in association with a Suitable pharmaceu 
tical excipient. Preferably, the active ingredient is employed 
at no more than about 20 weight percent of the pharmaceu 
tical composition, more preferably no more than about 15 
weight percent, with the balance being pharmaceutically 
inert carrier(s). 
An active compound is typically effective over a wide 
dosage range and is generally administered in a pharmaceu 
tically effective amount. It, will be understood, however, that 
the amount of the active ingredient actually administered 
will be determined by a physician, in the light of the relevant 
circumstances, including the condition to be treated, the 
chosen route of administration, the actual compound 
administered, the age, weight, and response of the individual 
patient, the Severity of the patient's Symptoms, and the like. 
For preparing Solid compositions Such as tablets, the 
principal active ingredient is mixed with a pharmaceutical 
excipient to form a Solid preformulation composition con 
taining a homogeneous mixture of a compound of the 
present invention. When referring to these preformulation 
compositions as homogeneous, it is meant that the active 
ingredient is dispersed evenly throughout the composition 
so that the composition may be readily Subdivided into 
equally effective unit dosage forms Such as tablets, pills and 
capsules. This solid preformulation is then subdivided into 
unit dosage forms of the type described above containing 
from, for example, 0.1 to about 500 mg of the active 
ingredient of the present invention. 
The tablets or pills of the present invention may be coated 
or otherwise compounded to provide a dosage form afford 
ing the advantage of prolonged action. For example, the 
tablet or pill can comprise an inner dosage and an outer 
dosage component, the latter being in the form of an 
envelope over the former. The two components can be 
Separated by an enteric layer which Serves to resist disinte 
gration in the Stomach and permit the inner component to 
pass intact into the duodenum or to be delayed in release. A 
variety of materials can be used for Such enteric layers or 
coatings, Such materials including a number of polymeric 
acids and mixtures of polymeric acids with Such materials as 
shellac, cetyl alcohol, and cellulose acetate. 
The liquid forms in which the novel compositions of the 
present invention may be incorporated for administration 
orally or by injection include aqueous Solutions, Suitably 
flavored Syrups, aqueous or oil Suspensions, and flavored 
emulsions with edible oils. Such as corn oil, cottonseed oil, 
Sesame oil, coconut oil, or peanut oil, as well as elixirs and 
Similar pharmaceutical vehicles. 
By way of example, the radiation Sensitizer motexafin 
gadolinium is administered in a Solution containing 2 mM 
optionally in 5% mannitol USP/water (sterile and non 
pyrogenic Solution). Dosages of 0.1 mg/kg up to as high as 
about 23.0 mg/kg have been delivered, preferably about 3.0 
to about 15.0 mg/kg (for volume of about 90 to 450 mL) may 
be employed, optionally with pre-medication using anti 
emetics above about 6.0 mg/kg. The texaphyrin is admin 
istered via intravenous injection over about a 5 to 10 minute 
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period, followed by a waiting period of about 2 to 5 hours 
to facilitate intracellular uptake and clearance from the 
plasma and extracellular matrix prior to the administration 
of radiation. 
When employing radiation therapy, a palliative course of 
30 Gy in ten (10) fractions of radiation are typically admin 
istered over consecutive dayS eXcluding weekends and holi 
days. In the treatment of brain metastases, whole brain 
megavolt radiation therapy is delivered with 60Co tele 
therapy or a >4 MV linear accelerator with isocenter dis 
tances of at least 80 cm, using isocentric techniques, 
opposed lateral fields and exclusion of the eyes. A minimum 
dose rate at the midplane in the brain on the central axis is 
about 0.5 Gy/minute. 
Radiation Sensitizers may be administered before, or at 
the Same time as, or after administration of the ionizing 
radiation, preferably before. The radiation Sensitizer may be 
administered as a Single dose, as an infusion, or it may be 
administered as two or more doses Separated by an interval 
of time. Where the radiation sensitizer is administered as 
two or more doses, the time interval between administra 
tions may be from about one minute to a number of days, 
preferably from about 5 minto about 1 day, more preferably 
about 4 to 5 hr. The dosing protocol may be repeated, from 
one to ten or more times, for example. Dose levels for 
radiation Sensitization using motexafin gadolinium may 
range from about 0.05 umol/kg to about 20 limol/kg admin 
istered in Single or multiple doses (e.g. before each fraction 
of radiation). A lower dosage range is presently preferred for 
intra-arterial injection or for impregnated Stents. In the case 
ofteXaphyrins incorporating or conjugated to a radioisotope, 
the additional administration of radiation as a co-therapeutic 
agent is optional. 
Administering a radiation Sensitizer to a mammalian host 
bearing atheroma cells may be prior to, concurrent with, or 
following vascular intervention, and the interventon is fol 
lowed by radiation. The administration may begin prior to, 
Such as about 24–48 hours prior to, or at a time roughly 
accompanying vascular intervention, for example. Multiple 
or Single treatments prior to, at the time of, or Subsequent to 
the procedure may be used. “Roughly accompanying the 
vascular intervention” refers to a time period within the 
ambit of the effects of the vascular intervention. Typically, 
an initial dose of the sensitizer and radiation will be within 
1-24 hours of the vascular intervention, preferably within 
about 5-24 hours thereafter. Follow-up dosages may be 
made at weekly, biweekly, or monthly intervals. Design of 
particular protocols depends on the individual Subject, the 
condition of the Subject, the design of dosage levels, and the 
judgment of the attending practitioner. In the methods of the 
invention involving the administration of a compound that 
catalyzes the production of one or more reactive oxygen 
Species from a cellular metabolite having a Standard bio 
chemical reduction potential more negative than the Stan 
dard biochemical reduction of oxygen/hydrogen peroxide, a 
Source or precursor of Such cellular metabolite is 
co-administered either before, contemporaneously with the 
catalytic agent or Subsequent to its administration; either or 
both agents may be administered Systemically or locally 
(e.g., by intra-arterial injection). 
The following formulation examples illustrate represen 
tative pharmaceutical compositions of the present invention. 
Formulation Example 1 
Hard gelatin capsules containing the following ingredi 











Ingredient Quantity (mg/capsule) 
Active Ingredient 3O.O 
Starch 3OS.O 
Magnesium stearate 5.0 
The above ingredients are mixed and filled into hard 
gelatin capsules in 340 mg quantities. 
Formulation Example 2 
A tablet formula is prepared using the ingredients below: 
Ingredient Quantity (mg/tablet) 
Active Ingredient 25.0 
Cellulose, microcrystalline 2OO.O 
Colloidal silicon dioxide 1.O.O 
Stearic acid 5.0 
The components are blended and compressed to form 
tablets, each weighing 240 mg. 
Formulation Example 3 
Tablets, each containing 30 mg of active ingredient, are 
prepared as follows: 
Ingredient Quantity (mg/tablet) 
Active Ingredient 30.0 mg 
Starch 45.0 mg 
Microcrystalline cellulose 35.0 mg 
Polyvinylpyrrolidone (as 10% solution in sterile 4.0 mg 
water) 
Sodium carboxymethyl starch 4.5 mg 
Magnesium stearate 0.5 mg 
Talc 1.0 mg 
Total 120 mg 
The active ingredient, Starch and cellulose are passed 
through a No. 20 mesh U.S. sieve and mixed thoroughly. 
The solution of polyvinylpyrrolidone is mixed with the 
resultant powders, which are then passed through a 16 mesh 
U.S. sieve. The granules so produced are dried at 50 to 60 
C. and passed through a 16 mesh U.S. sieve. The Sodium 
carboxymethyl Starch, magnesium Stearate, and talc, previ 
ously passed through a No. 30 mesh U.S. sieve, are then 
added to the granules which, after mixing, are compressed 
on a tablet machine to yield tablets each weighing 120 mg. 
Formulation Example 4 
Capsules, each containing 40 mg of medicament are made 
as follows: 
Ingredient Quantity (mg/capsule) 
Active Ingredient 40.0 mg 
Starch 109.0 mg 
Magnesium stearate 1.0 mg 
Total 150.0 mg 
The active ingredient, Starch, and magnesium Stearate are 
blended, passed through a No. 20 mesh U.S. sieve, and filled 
into hard gelatin capsules in 150 mg quantities. 
US 6,825,186 B1 
23 
Formulation Example 5 
Suspensions, each containing 50 mg of medicament per 
5.0 mL dose are made as follows: 
Ingredient Amount 
Active Ingredient 50.0 mg 
Xanthan gum 4.0 mg 
Sodium carboxymethyl cellulose (11%) 50.0 mg 
Microcrystalline cellulose (89%) 
Sucrose 1.75 g 
Sodium benzoate 10.0 mg 
Flavor and Color G.V. 
Purified water to 5.0 mL. 
The active ingredient, Sucrose and Xanthan gum are 
blended, passed through a No. 10 mesh U.S. sieve, and then 
mixed with a previously made Solution of the microcrystal 
line cellulose and Sodium carboxymethyl cellulose in water. 
The Sodium benzoate, flavor, and color are diluted with 
Some of the water and added with stirring. Sufficient water 
is then added to produce the required Volume. 
Formulation Example 6 
Capsules are made as follows: 
Ingredient Quantity (mg/capsule) 
Active Ingredient 15.0 mg 
Starch 407.0 mg 
Magnesium stearate 3.0 mg 
Total 425.0 mg 
The active ingredient, Starch, and magnesium Stearate are 
blended, passed through a No. 20 mesh U.S. sieve, and filled 
into hard gelatin capsules in 425.0 mg quantities. 
Formulation Example 7 
An injectable preparation buffered to a pH of 7.4 is 
prepared having the following composition: 
Ingredients Amount 
Active Ingredient 0.2 g 
Sodium Phosphate Buffer Solution (0.8M) 10.0 ml 
DMSO 1.0 ml 
WFI q.S. to 100 ml 
Formulation Example 8 
An injectable formulation is prepared having the follow 
ing composition: 
Ingredients Amount (w/v %) 
Motexafin gadolinium O.23% 
Motexafin lutetium O.20% 
Mannitol (USP) 5.0% 
Acetic Acid (5%) adjust to pH 5.4 
Sterile WFI (USP) q.s. to 100% 
The formulation is filled into a glass vials, which are then 
purged with nitrogen to exclude oxygen from the head Space 











It may be desirable or necessary to introduce the phar 
maceutical composition to the brain, either directly or indi 
rectly. Direct techniques usually involve placement of a drug 
delivery catheter into the host's Ventricular System to bypass 
the blood-brain barrier. One such implantable delivery sys 
tem used for the transport of biological factors to specific 
anatomical regions of the body is described in U.S. Patent 
5,011,472 which is herein incorporated by reference. 
Indirect techniques, which are generally preferred, uSu 
ally involve formulating the compositions to provide for 
drug latentiation by the conversion of hydrophilic drugs into 
lipid-Soluble drugs. Latentiation is generally achieved 
through blocking of the hydroxy, carbonyl, Sulfate, and 
primary amine groups present on the drug to render the drug 
more lipid Soluble and amenable to transportation acroSS the 
blood-brain barrier. Alternatively, the delivery of hydro 
philic drugs may be enhanced by intra-arterial infusion of 
hypertonic Solutions which can transiently open the blood 
brain barrier. 
Other suitable formulations for use in the present inven 
tion can be found in Remington's Pharmaceutical Sciences, 
Mace Publishing Company, Philadelphia, Pa. 17th ed. 
(1985). 
The following examples are offered to illustrate this 
invention and are not to be construed in any way as limiting 
the Scope of this invention. 
EXAMPLES 
In the examples below, the following abbreviations have 
the following meanings. If an abbreviation is not defined, it 
has its generally accepted meaning. 
BSO = buthionine sulfoximine 
CdTex = compound of formula II where M is Cd' 
CoTex = compound of formula II where M is Co." 
Di-amino GdTex = formula II where M is Gd" except 
(as shown in formula I) is amino 
compound O 
that both R' 
propyl 
compound O 
that both R' 
propyl 
formula II where M is Lu" except 
(as shown in formula I) is amino 
Di-amino LuTex = 
DyTex = compound of formula II where M is Dy" 
EuTex = compound of formula II where M is Eu" 
Fe(Tex).O = mu-oxo dimer of two compounds of formula II 
where M is Fe?" 
GdTex = motexafin godolinium (formula II where M is Gd") 
HEPES = hydroxyethylpiperizine ethane sulfonic acid 
HPLC = high performance liquid chromatography 
LuTex = motaxafin lutetium (formula II where M is Lu") 
mg = milligram 
mL = milliliter 
= millimeter 
mM = millimolar 
MTex = compound of formula II where M is Mn." 
immol = millimols 
= nanometer 
psi = pounds per square inch 
RPM 164O = a commercially available culture medium 
SmTex = compound of formula II where M is Sm" 
"YTex = compound of formula II where M is Y" 
AtL = microliter 
puM = micromolar 
Example 1 
Oxidation of NADPH Under Approximate Physiologic Con 
ditions 
This example measures radiation Sensitization potential as 
a function of oxidation of the cellular metabolite NADPH. 
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1A. Materials and Method 
The following Stock Solutions were prepared: 
Stock NADPH (Sigma N 7505) (prepared fresh daily): 
12.2 mg/(10 mL. 833.4 mg/mmol)=1.46 mM 
Stock GdTex: 5.76 mg/(10.0 mL water. 1148 mg/mmol)= 
501.7 uM 
Stock 4x Buffer: 200 mM HEPES, pH 7.5; 400 mM NaCl; 
O4 mM EDTA 
Stock LuTex: 5.02 mg/(10.0 mL waterx1166 mg/mmol)= 
431 uM 
These were combined to form the reaction mixtures 
analyzed by HPLC, for example: 
250 uL 4x Buffer, 250 uL NADPH Stock, 427 uL Water, 
72.7 uL GdTex Stock 
250 u 4x Buffer, 250 uL NADPH Stock, 457.7 uL Water, 
42.3 ul. LuTex Stock 
The HPLC Method employed was as follows: 
1. HPLC Operating Parameters 
System-HPLC system capable of delivering gradient 
mobile phase 
Detector wavelength-260 nm 
Injection Volume-20 till 
Pressure-ca.2000 psi 
Column Temperature-40 C. 
Column-Nucleogel DEAE 60-7125x4 mm 
2. Mobile Phase 
Solution A–0.75 M KHPO, pH 3.8 
Solution B-0.016 M KHPO, pH 3.8 
Time (min.) Flow (mL/min) A (%) B (%) 
inital 1.O 5 95 
5 1.O 5 95 
3O 1.O 8O 2O 
31 1.5 5 95 
39 1.O 5 95 
40 1.O 5 95 
A reaction mixture was prepared containing NADPH, 
water and sufficient buffer to maintain the solution at pH 7.5. 
Texaphyrin, 0.1 molar equivalent to the NADPH, was added 
to this reaction mixture, Vortexed briefly, and then the 
solution placed in the HPLC sampler for immediate injec 
tion. Further injections were made at appropriate time 
points, whereupon the integrated peak areas of both NADPH 
and NADP were measured and used to calculate the extent 
of reaction at a given time point. 
Provided that the amount of texaphyrin was sufficiently 
low relative to substrate, the percentage of NADP gener 
ated by the reaction plotted against time initially gave a 
Straight line. (For LuTeX, it was necessary to drop the 
catalyst concentration to ca. 0.05 equivalent.) The slope of 
initial time points (eg., plotting as mM concentration vs time 
in hours) provided a rate which was used as a point in a 
saturation (Michaelis-Menton) plot. This process was 
repeated at various concentrations of NADPH. Data (in 
triplicate) was fitted to the Michaelis-Menton equation 
(initial reaction velocity/catalyst concentration)=(kx 
Substrate concentration)/(K+Substrate concentration), 
where substrate is NADPH, catalyst is texaphyrin complex, 
k is the first-order rate constant for the catalyst, and K is 
the dissociation (or Michaelis) constant for the catalyst/ 
substrate complex. For GdTex, k=0.049+0.003 min' and 
K=1.69+0.17 mM. For LuTex, k=0.119+0.011 min' 













The results of this analysis are depicted in FIGS. 1-6. 
FIGS. 1-3 illustrate triplicate runs for LuTex which runs are 
recited as LuTex A, LuTeX B and LuTeX C. FIGS. 4-6 
illustrate triplicate runs for GdTex which runs are recited as 
GdTex A, GdTex B and GdTex C 
These results evidence that in the presence ofteXaphyrins, 
NADPH was oxidized to NADP", and further that the test 
compounds have probable radiation Sensitization activity. 
1B. By following the procedure of Example 1A using a 
single concentration of NADPH and employing 0.1 equiva 
lent of test compound, the results illustrated in FIG. 16 were 
obtained. These results evidence that in the presence of the 
tested texaphyrins, NAPDH was oxidized to NADP, and 
further that the test compounds (with the exception of 
Mn"Tex) have probable radiation sensitization activity 
where NADPH is the reducing metabolite. 
Example 2 
Oxidation of AScorbate under Approximate Physiologic 
Conditions 
This example measures radiation Sensitization potential as 
a function the oxidation of ascorbate, employing an assay 
modified from Buettner, et al., Radiation Research 
145:532–541 (1996). 
2A. Materials and Method 
The following Stock Solutions were prepared: 
Stock ascorbic acid (Sigma A5960) (prepared fresh): 8.82 
mg/(25 mL 176.1 mg/mmol)=2.00 mM 
Stock GdTex: 5.72 mg/(10.0 mL water. 1148 mg/mmol)= 
498 uM 
Stock 4x Buffer: 200 mM HEPES, pH 7.5; 400 mM NaCl 
The Stock Solutions were prepared using ACS grade water 
(Aldrich 32,007-2). 4xbuffer was prepared using NaCl 
99.999% (Aldrich 20,443-9), HEPES (Gibco-BRL 11344 
025), and sodium hydroxide 99.99% (Aldrich 30,657-6), 
and was treated with Chelex(R) 100 (BioRad 143-2832) prior 
to use to remove trace iron contaminants. These were 
combined to form the reaction mixture analyzed by UV-vis 
spectroscopy: 400 u 4x Buffer, 200 till Ascorbic Acid 
Stock, 979.9 uL Water, 20.1 ul GdTex Stock. 
In brief, a reaction mixture was prepared containing 
ascorbate, buffer, and water. A lesser amount of texaphyrin 
catalyst, eg., 0.025 molar equivalent, was added to this 
reaction mixture, Vortexed briefly, and placed in a quartz 
cuvette (0.2,0.5, 1.0, 2.0, 5.0, or 10 mm path length as 
needed to give ca. 1.8 absorbance reading at 266 mm). The 
cuvette was placed in a UV-vis Spectrophotometer and the 
absorbance was read every 60 seconds for ten minutes. The 
absorbance at 266 nm plotted against time initially gaive a 
Straight line. The slope of initial time points (e.g., plotting as 
M concentration vs time in minutes) provided a rate which 
was used as a point in a Saturation (Michaelis-Menton) plot. 
This process was repeated at various concentrations of 
ascorbate. A background rate of ascorbate oxidation was 
also measured at each concentration of ascorbate using this 
procedure without GdTex catalyst. The resulting back 
ground rate of oxidation was Subtracted from the rate of 
oxidation in the presence of catalyst. Data was fitted to the 
Michaelis-Menton equation (initial reaction velocity/ 
catalyst concentration=(kxSubstrate concentration)(K+ 
Substrate concentration), where Substrate was ascorbate, 
catalyst was teXaphyrin complex, k is the first-order rate 
constant for the catalyst, and K is the dissociation (or 
Michaelis) constant for the catalyst/substrate complex. For 
GdTex, k=0.35 min-1 and K=1.06 mM. cit 
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Results 
The results of this analysis are depicted in FIG. 7 which 
results demonstrate that in the presence of GdTeX, ascorbate 
was oxidized and further that the test compounds have 
probable radiation Sensitization activity. 
2B 
By following the procedure of Example 2A and substi 
tuting motexafin gadolinium with motexafin lutetium it was 
determined that ascorbate was oxidized in the presence of 
motexafin lutetium but to a lesser extent than in the presence 
of motexafin gadolinium. Thus, taken in conjunction with 
the results of Example 1, probable radiation Sensitization 
activity of motexafin lutetium is associated with a NADPH 
metabolic pathway, whereas the probable radiation Sensiti 
Zation activity of motexafin gadolinium is more Strongly 
asSociated with an ascorbate metabolic pathway, Suggesting 
that co-administration of both motexafin gadolinium and 
motexafin lutetium can combine to more effectively catalyze 
the production of hydrogen peroxide from both pathways. 
2C 
By following the procedure of Example 2A and substi 
tuting iron porphyrin for the texaphyrin, it is indicated that 
ascorbate can be similarly oxidized and that the test com 
pound will have probable radiation Sensitization activity. 
2D 
By following the procedure of Example 2A, using an 
initial ascorbate concentration of 1.23 mM and a texaphyrin 
concentration of 61.5 uM, the results summarized in below 
in Table 1 were obtained. 
TABLE 1. 
Texaphyrin Ascorbate Depletion initial rate (Vo) uM/min 
LuTex -2.33 0.16 
ErTex -3.55 
DyTex -5.92 
GdTex -9.98 1.03 
EuTex -9.45 0.91 
SmTex -10.45 OSO 





Di-amino MinTex -3.4 
Di-amino GdTex -10.3 
Di-amino LuTex -9.7 
These results eivdence that in the presence of the tested 
teXaphyrins, ascorbate was oxidized, and further that the test 
compounds have probable radiation Sensitization activity. 
Example 3 
Production of HO, in the Presence of NADPH under 
Approximate Physiologic Conditions 
This example illustrates the measurement of hydrogen 
peroxide generation from the oxidation of NADPH, as an 
indicator of radiation Sensitization potential. 
3A. Materials and Method 
The following Stock Solutions were prepared: 
Stock NADPH (Sigma N 7505) (prepared fresh): 10.14 
mg/(10 mLx833.4 mg/mmol)=1.217 mM 
Stock LuTex: 5.02 mg/(10.0 mL waterx1166 mg/mmol)= 
431 M 
Stock 4x Buffer: 200 mM HEPES, pH 7.5; 400 mM NaCl 
These were combined to form the reaction mixture: 200 
uL 4x Buffer, 200 ul NADPH Stock, 371.8 uL Water, 28.2 
till LuTex Stock. This was analyzed as indicated below. As 











added was prepared as above, with Suitable adjustment of 
the Volume of water, and analyzed concurrently. In Similar 
manner, a Solution was prepared as above except that 2 till 
catalase (Boeringer-Mannheim 106 836, now Roche 
Molecular Biochemicals, Indianapolis, Ind.) was added, and 
analyzed concurrently. 
A reaction mixture was prepared containing NADPH, 
buffer, and water. Texaphyrin catalyst, e.g., 0.05 molar 
equivalent, was added to this reaction mixture, Vortexed 
briefly, and incubated at ambient temperature in the dark. 
Aliquots of 50 L were removed every 20 minutes, and added 
to a reagent which produces a characteristic color in the 
presence of HO (Bioxytech(RHO-560TM, R&D Systems, 
Minneapolis, Minn.). A 25 mM solution of HO was 
prepared by dilution of 30% HO. The absorbance at 240 
nm was used to Standardize this Solution, which was further 
diluted and used to construct a standard HO curve at 560 
nm in conjunction with the H2O colorimetrc reagent. Fur 
ther details on the use of the Bioxytech(RHO-560TM kit are 
available from the package insert. 
Measurements of the absorbance at 560 nm (with appro 
priate Subtraction of the background absorbance of the 
reagent at this wavelength) were made of Samples taken at 
the various time points. 
Results 
After conversion of absorbance to H2O, a plot of H2O 
VS. time showed that HO was produced only in the reaction 
mixture which contained LuTeX and no catalase. Approxi 
mately 40 uM HO was produced over the course of 100 
minutes. The results of this example are illustrated in FIG. 
8, which demonstrates that in the presence of LuTex, 
NADPH generates hydrogen peroxide. The test compound 
has probable radiation Sensitization activity. 
3B 
By following the procedure of Example 3A and substi 
tuting redox cycling agents for the texaphyrin, it is indicated 
that reactive oxygen Species can be similarly generated and 
that the test compound will have probable radiation Sensi 
tization activity. Suitable redox cycling agents for use in this 
example include, for instance, alloxan, phenazine 
methoSulfate, menadione, copper/putrescine/pyridine, meth 
ylene blue, paraduat, doxorubicin and ruthenium (II) tris 
(1,10-phenanthroline-5,6-dione). To the extent these redox 
cycling agents do not preferentially accumulate in tumors, 
Such molecules can be coupled to a compound that does 
preferentially accumulate in a tumor. 
Example 4 
Production of HO in the Presence of Ascorbate under 
Approximate Physiologic Conditions 
This example illustrates the measurement of hydrogen 
peroxide generation from the oxidation of ascorbate, as an 
indicator of radiation Sensitization potential. 
In this example, the following Stock Solutions were pre 
pared: 
Stock ascorbic acid (Sigma A5960) (prepared fresh): 9.98 
mg/(10 mLx176.12 mg/mmol)=5.67 mM 
Stock GdTex: 5.76 mg/(10.0 mL waterx1148 mg/mmol)= 
502 uM 
Stock 4x Buffer: 200 mM HEPES, pH 7.5; 400 mM NaCl 
These were combined to form the reaction mixture: 200 
till 4x Buffer, 39 it ascorbic acid Stock, 517.3 ul. Water, 
43.7 till GdTex Stock. The reaction mixture was analyzed for 
hydrogen peroxide as indicated above. As a control, a 
Solution in which complex was not added was prepared as 
above, with Suitable adjustment of the volume of water, and 
analyzed concurrently. 
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Measurements of the absorbance at 560 nm (with appro 
priate Subtraction of the background absorbance of the 
reagent at this wavelength) were made of Samples taken at 
the various timepoints. It was noted that the control Solution 
gave a uniform background absorbance which was similar at 
all time points, whereas the mixture containing GdTeX gave 
an increasing amount of absorbance over time. (Sugars are 
known to produce high background absorbance in this assay, 
See manufacturers insert for details.) 
Results 
After conversion of absorbance to H2O, a plot of H2O2 
vs. time showed that HO was produced in the reaction 
mixture which contained GdTex. The plot (FIG. 9) was 
linear over the time interval of 75 to 200 minutes, with 
approximately 35 uM HO produced over this interval. This 
demonstrates that in the presence of GdTeX, ascorbate 
generates hydrogen peroxide. The test compound has prob 
able radiation Sensitization activity. 
Example 5 
Production of HO, by the Gadollnium(III) Complex of 
Texaphyrin in the Presence of Ascorbate under Cell Culture 
Conditions 
The proliferation of MES-SA human uterine cells 
(Harker, W. G.; MacKintosh, F. R.; Sikic, B. I. Cancer Res. 
1983, 43,4943–4950) grown in RPMI-1640 medium in the 
presence of ascorbate or complex was used to assess the 
formation of hydrogen peroxide under cell culture condi 
tions. 
5A. Materials and Methods 
MES-SA cells were allowed to adhere to (4) 96-well 
microtiter plates (4000 cells per well) overnight in 160 uL 
RPMI medium. Stock ascorbate 3.0 mM in medium (80 uL) 
was serially diluted (1:3) in rows B through F(discarding the 
final 80 ul). Row G was used for no-ascorbate control. 
Stock solutions of GdTex (2 mM in 5% mannitol) diluted in 
medium and 5% mannitol were prepared and added to the 
plates to give a final volume of 200 till in all wells. Columns 
2 and 3 contained 100 uM GdTex; columns 4 and 5 
contained 75 uM GdTex, columns 6 and 7 contained 50 uM 
GdTex; columns 8 and 9 contained 25 uM GdTex; and 
columns 10 and 11 contained no GdTeX (all concentrations 
final). Final mannitol concentration was 0.25% in all wells. 
The plates were incubated at 37 C. under a 5% CO2/95% air 
atmosphere. Complex-containing medium was eXchanged 
for fresh medium after 5 hours, and plates were incubated an 
additional 72 hours prior to analysis for viability using the 
tetrazolium dye, MTT (Mosmann, T. J. Immunol. Methods 
1983, 65, 55-63). In brief, 20 uL MTT dye (Sigma 
Chemical, St. Louis, Mo., catalogue no. M 2128, 5 mg/mL 
Solution in phosphate buffered Saline) was added to cells in 
media to give a final volume of 200 lull. The plates were 
incubated at 37 C. for ca. 2 hours, whereupon the media 
was removed and isopropyl alcohol (100.uL/well) was 
added. Plates were vortexed for ca. 3 minutes to dissolve 
MTYT formazan, then read on a microplate reader at 
560-650 nm. Plate absorbances were normalized to wells 
containing neither ascorbate nor GdTeX to allow plate to 
plate comparison. Data for each concentration of GdTeX and 
ascorbate is the average of eight wells. 
Results 
AScorbate alone had no inhibitory effect at concentrations 
at or below 333 uM in the absence of GdTex, whereas 
complete cytotoxicity was observed at all concentrations of 
GdTeX at this concentration of ascorbate. GdTeX had no 
cytotoxic effect in the absence of ascorbate. A dose-response 
was observed towards GdTex at 111 uM and 62.5 uM 











The results of this analysis are illustrated in FIG. 10. The 
toxicity of cells to the combination of Sufficient concentra 
tions of GdTex and ascorbate is attributed to the production 
of toxic quantities of hydrogen peroxide and Suggests that 
motexafin gadolinium has probable radiation Sensitization 
activity. 
Example 6 
Production of HO, by the Lutetium(III) Complex of Texa 
phyrin in the Presence of Ascorbate under Cell Culture 
Conditions 
The proliferation of MES-SA human uterine cells grown 
in RPMI-1640 medium in the presence of ascorbate and 
LuTeX was used to assess the production of hydrogen 
peroxide under cell culture conditions following the protocol 
outlined in the previous example. AScorbate alone had no 
inhibitory effect at concentrations at or below 333 uM in the 
absence of LuTeX, whereas a dose-response was observed 
towards LuTex at this concentration. No inhibitory effect 
was seen at lower concentrations of ascorbate. LuTeX had no 
inhibitory effect in the absence of ascorbate. 
The results of this analysis are illustrated in FIG. 11. The 
toxicity of cells to the combination of Sufficient concentra 
tions of LuTex and ascorbate is attributed to the production 
of toxic quantities of hydrogen peroxide and Suggests that 
LuTeX has probable radiation Sensitization activity. 
Example 7 
Production of HO, by the Lutetium(III) Complex of Texa 
phyrin in the Presence of NADPH under Cell Culture 
Conditions 
The proliferation of EMT-6 mouse mammary sarcoma 
(Rockwell, S. C., et al., J. Natl. Cancer Inst. 1972, 49, 
735-749) cells grown in RPMI-1640 medium in the pres 
ence of NADPH and motexafin lutetium was used to assess 
the production of hydrogen peroxide under cell culture 
conditions following the protocol outlined in the previous 
example. NADPH alone had no inhibitory effect at concen 
trations at or below 1000 uM in the absence of motexafin 
lutetium, whereas a dose-response was observed towards 
motexafin lutetium at this concentration and at 333 uM. No 
inhibitory effect was seen at lower concentrations of 
NADPH. Motexafin lutetium had no inhibitory effect in the 
absence of NADPH. 
The results of this analysis are illustrated in FIG. 12. The 
toxicity of cells to the combination of Sufficient concentra 
tions of motexafin lutetium and NADPH is attributed to the 
production of toxic quantities of hydrogen peroxide and 
Suggests probable radiation Sensitization activity for 
motexafin lutetium. 
Example 8 
Production of HO, by the Gadolinium(III) Complex of 
Texaphyrin in the Presence of NADPH under Cell Culture 
Conditions 
The proliferation of EMT6 mouse mammary sarcoma 
(Rockwell, S. C., et al., J. Natl. Cancer Inst. 1972, 49, 
735-749) cells grown in RPMI-1640 medium in the pres 
ence of NADPH and GdTex was used to assess the produc 
tion of hydrogen peroxide under cell culture conditions 
following the protocol outlined in the previous example. 
NADPH alone had no inhibitory effect at concentrations at 
or below 1000 uM in the absence of GdTex, whereas a 
dose-response was observed towards GdTeX at this concen 
tration and at 333 uM. No inhibitory effect was seen at lower 
concentrations of NADPH. GdTex had no inhibitory effect 
in the absence of NADPH. 
The results of this analysis are illustrated in FIG. 13. The 
toxicity of cells to the combination of Sufficient concentra 
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tions of GdTex and NAD(P)H is attributed to the production 
of toxic quantities of hydrogen peroxide and Suggests that 
motexafin gadolinium has probable radiation Sensitization 
activity, albeit less than that of motexafin lutetium in a 
NADPH dominated metabolic pathway. 
Example 9 
The Cytotoxic Effect of L-Buthionine-S,R)-Sulfoximine 
(BSO) in the presence of the Gadolinium(III) Complex of 
Texaphyrin under Cell Culture Conditions 
The proliferation of MES-SA human uterine cells grown 
in McCoys 5A medium in the presence of a thiol depleting 
agent (BSO) or GdTex was used to assess the combined 
effect of these agents. The protocol outlined in the previous 
example was followed, with the following changes: 
1. The serially diluted compound was 200 uM BSO 
(Sigma Chemical, St. Louis, Mo., catalogue no. G1404). 
2. The cells were allowed to incubate in the presence of 
the two drugs for ca. 72 hours, prior to exchange of media 
and analysis using the calorimetric (MTT) assay, as 
described, e.g., in Example 5. 
GdTex had an inhibitory effect of ca. 50% in the absence 
of BSO. For clarity, the data has been normalized to discount 
the cytotoxic effect of GdTex alone. BSO alone had an 
inhibitory effect in the absence of GdTex of about 10% at the 
highest (50 uM) concentration tested. In the presence of 
increasing amounts of GdTeX, an increase in the cytotoxic 
dose response of the cells towards BSO is seen. This 
indicates that cooperative cell growth inhibition occurs in 
the presence of the two agents. 
The results of this example are illustrated in FIG. 14. 
Example 10 
The Cytotoxic Effect of the Gadolinium(III) Complex of 
TeXaphyrin and Ionizing Radiation, with and without 
L-Buthionine-S,R)-Sulfoximine (BSO) under Cell Culture 
Conditions 
The response of ME-SA cells to ionizing radiation was 
Studied using the microtiter plate format to confirm radiation 
Sensitization potential. This assay is used to assess rapidly 
the effects of irradiation under a variety of conditions. 
10A. Materials and Methods 
MES-SA cells were incubated at 37 C. and allowed to 
adhere to 96-well microtiter plates (1000 cells per well) 
overnight in 160 ul McCoys 5A containing 10% FBS 
(Gibco-BRL) and ca. 2% penicillin/streptomycin solution 
(Sigma). BSO or media (20 uL) was added, respectively to 
test and control wells, 24 h prior to irradiation. Metallotexa 
phyrin complex (up to 100 uM) was added to the test wells 
to give a final volume of 200 u, 18-24 h prior to irradiation. 
Plates were irradiated using a 137Cs irradiator (Model 40 
Gammaceii, J. L. Shepherd & ASSoc., San Fernando, Calif.) 
at a dose rate of 33.25 Rad/min. A lead brick (2" diameter) 
was positioned to protect a column of wells (no. 11) from 
ionizing radiation. Plate absorbances were normalized to 
Shielded Wells to allow plate-to-plate comparison. Control 
experiments demonstrated that data from columns 1-9 were 
not effected by Shielding. Reversing the position of texa 
phyrin complex-containing wells had no effect on assay 
outcome. Medium was exchanged immediately after 
irradiation, and plates were incubated an additional 120 h 
prior to analysis for viability using the MTT assay (as 
described, e.g., in Example 5). 
Results 
Treatment of MES-SA cells with up to 50 uM GdTex for 
24 h prior to irradiation had a Small effect on apparent 
viability, after adjustment for the effect of GdTex alone 











at the 100 uM GdTex concentration. In the parallel experi 
ment in which all cells were pre-incubated with 100 uM 
BSO, a greater GdTeX-dependent decrease in apparent 
viability was observed (FIG. 17B). The effect of BSO 
appeared to be dose-dependent from 0 to 100 uM, and 
leveled off at higher BSO concentrations (data not shown). 
These results corroborate the correlation between radia 
tion Sensitization potential and reactive oxygen Species 
production from a cellular metabolite having a Standard 
biochemical reduction potential more negative than the 
Standard biochemical reduction of oxygen/hydrogen perOX 
ide. Additionally, these results indicate that the radiation 
Sensitization potential of GdTeX, and presumably of other 
reactive oxygen Species-producing Sensitizers, can be aug 
mented by co-administration of a thiol-depleting agent or 
other agents that interfere with cellular metabolic pathways. 
10B. In corresponding experiments Sensitization was not 
obtained when LuTeX was Substituted for GdTeX, or when 
RPMI prepared with dialyzed serum (an ascorbate-free 
medium) was substituted for McCoys 5A with normal serum 
(an ascorbate containing medium). 
Example 11 
Radiation Sensitization as Determined by Clonogenic ASSay 
The response of MES-SA cells to ionizing radiation was 
Studied using a clonogenic assay format to confirm radiation 
Sensitization potential. 
Materials and Methods 
MES-SA cells (200 to 5,000 cells per dish) were plated in 
T-25 flasks in 8.5 mL McCoys 5A containing 10% FBS 
(Gibco-BRL) and ca. 2% penicillin/streptomycin solution 
(Sigma) and incubated at 37° C. overnight. Stock BSO, 
ascorbate, GdTex (or a control 5% mannitol) solutions were 
prepared and 0.5 mL of each added to each flask to give a 
final volume of 10 mL (final concentrations of BSO, ascor 
bate and GdTex were 100 uM, 5 uM and 50 uM, 
respectively) and the cells incubated for 24 hr, whereupon 
the flasks were irradiated using a 137Cs irradiator (Model 40 
Gammacell, J. L. Shepherd & Assoc., San Fernando, Calif.) 
at a dose rate of 0.805 Gy/min. Medium was removed 
immediately after irradiation, the cells were washed with 
fresh medium (5.0 mL) followed by the addition of fresh 
medium (10 mL) and incubation for an additional 11 days. 
Colonies were fixed and stained with 1% crystal violet and 
then counted. 
Results 
As illustrated in FIG. 18, treatment of MES-SA cells with 
either 50 uM GdTex or 100 uM BSO for 24 h prior to 
irradiation had a relatively Small effect on clonogenic Sur 
vival as a function of radiation. Co-administration of 50 uM 
GdTex and 100 uM BSO resulted in a radiation response 
Significantly greater than the Sum of the responses obtained 
from them individually. 
These results demonstrate that sensitization of the effects 
of ionizing radiation by GdTeX can be confirmed in a 
clonogenic assay using ascorbate-containing medium, and 
that the co-administration of GdTex and BSO synergistically 
enhances the effects of ionizing radiation. 
Example 12 
The Cytotoxic Effect of Antimycins A and the Gadolinium 
(III) Complex of Texaphyrin under Cell Culture Conditions 
The proliferation of MES-SA human uterine cells grown 
in McCoys 5A medium in the presence of the thiol depleting 
agent BSO, with varying concentrations of a mitochondrial 
inhibitor (Antimycins A) and GdTex was used to assess the 
combined effect of these agents. 
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Materials and Methods 
MES-SA cells were incubated at 37 C. and allowed to 
adhere to 96-well microtiter plates (2000 cells per well) 
overnight in 180 ul McCoys 5A containing 10% FBS 
(Gibco-BRL) and ca. 2% penicillin/streptomycin solution 
(Sigma). BSO (20 uL) was added to all wells followed by 
incubation for a further 24 h. The medium was exchanged 
and Antimycins A was Serially diluted at concentrations 
ranging from 0 to 20 uM and after 0.5 hr metallotexaphyrin 
complex (up to 100 uM) was added to the test wells to give 
a final volume of 200 u, followed by incubation for 20 h, 
whereupon the medium was exchanged and the plates were 
incubated an additional 52 h prior to analysis for viability 
using the MTT assay. 
Results 
In the presence of increasing amounts of GdTeX, an 
increase in the cytotoxic dose response of the cells towards 
Antimycins A is seen. This indicates that cooperative cell 
growth inhibition occurs in the presence of the two agents. 
The results of this example are illustrated in FIG. 19. 
From the foregoing description, various modifications and 
changes in the composition and method will occur to those 
skilled in the art. All Such modifications coming within the 
Scope of the appended claims are intended to be included 
therein. 
What is claimed is: 
1. A method of inducing targeted oxidative StreSS, in the 
absence of ionizing radiation, in cells in a mammalian host 
bearing a tumor or atheroma or other neoplastic tissue, 
which method comprises: 
a) administering to Said mammalian host a metal contain 
ing texaphyrin of Formula I 
wherein M is a divalent metal cation or a trivalent metal 
cation; 
R" to R' as well as R7 and R are independently 
Selected from the group consisting of hydrogen, 
carboxyl, carboxylalkyl, acyl, acylamino, 
aminoacyl, alkyl, Substituted alky (particularly 
hydroxyalkyl or aminoalkyl, and especially where 
R" is hydroxypropyl or aminopropyl), alkenyl, Sub 
Stituted alkenyl, alkoxy, Substituted alkoxy, aryl, 
heteroaryl, heterocyclic, halo, hydroxyl, nitro, and a 
Saccharide; 
R and R are independently selected from the group 
consisting of hydrogen, carboxyl, carboxylalkyl, 











other than iodoalkyl, alkenyl, Substituted alkenyl, 
alkoxy, Substituted alkoxy, aryl, heteroaryl, 
heterocyclic, halo other than iodo, hydroxyl, nitro, 
and a Saccharide; 
R and R' to R' are independently selected from the 
group consisting of hydrogen, alkyl, Substituted 
alkyl, alkoxy, Substituted alkoxy, carboxyl, 
carboxylalkyl, acyl and acylamino; and 
the charge, Z, is an integer having a value less than or 
equal to 5, that preferentially accumulates in tumor 
or atheroma or other neoplastic tissue cells and 
catalyzes the production of one or more reactive 
oxygen Species from a cellular metabolite having a 
reduction potential more negative than that of 
molecular oxygen; 
b) optionally, allowing Sufficient time for said agent to 
preferentially accumulate in the cells of the tumor, 
atheroma or other neoplastic tissue; and 
c) administering to said mammalian host a cellular 
metabolite Such as to increase the reactive oxygen 
Species production in the tumor or atheroma or other 
neoplastic tissue. 
2. The method of claim 1 wherein the reactive oxygen 
Species is catalyzed from ascorbate and ascorbate is admin 
istered to Said mammalian host. 
3. The method of claim 1 wherein the reactive oxygen 
species is catalyzed from NAD(P)H and NAD(P)H is 
administered to Said mammalian host. 
4. A method of inducing targeted oxidative StreSS in cells 
in a mammalian host bearing a tumor or atheroma or other 
neoplastic tissue, which method comprises: 
a) administering to said mammalian host an agent, 
wherein Said agent is motexafin gadolium or motexafin 
lutetium or mixtures thereof, that preferentially accu 
mulates in tumor or atheroma or other neoplastic tissue 
cells and catalyzes the production of one or more 
reactive oxygen Species from a cellular metabolite; 
b) optionally, allowing Sufficient time for said agent to 
preferentially accumulate in the cells of the tumor, 
atheroma or other neoplastic tissue; and 
c) administering to said mammalian host a cellular 
metabolite Such as to increase the reactive oxygen 
Species production in the tumor or atheroma or other 
neoplastic tissue wherein the reactive oxygen Species is 
catalyzed from ascorbate and ascorbate is administered 
to Said mammalian host. 
5. A method of inducing targeted oxidative StreSS, in cells 
in a mammalian host bearing a tumor or atheroma or other 
neoplastic tissue, which method comprises: 
a) administering to said mammalian host an agent Selected 
from motexafin gadolinium, motexafin lutetium or mix 
tures thereof, that preferentially accumulate in tumor or 
atheroma or other neoplastic tissue cells and catalyzes 
the production of one or more reactive oxygen Species 
from a cellular metabolite 
b) optionally, allowing Sufficient time for said agent to 
preferentially accumulate in the cells of the tumor, 
atheroma or other neoplastic tissue; and 
c) administering to said mammalian host a cellular 
metabolite Such as to increase the reactive oxygen 
Species production in the tumor or atheroma or other 
neoplastic tissue. 
k k k k k 
  
